US20070149441A1 - Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same - Google Patents

Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same Download PDF

Info

Publication number
US20070149441A1
US20070149441A1 US11/706,922 US70692207A US2007149441A1 US 20070149441 A1 US20070149441 A1 US 20070149441A1 US 70692207 A US70692207 A US 70692207A US 2007149441 A1 US2007149441 A1 US 2007149441A1
Authority
US
United States
Prior art keywords
substituted
derivatives
group
halogen
phosphorous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/706,922
Inventor
Daniel Aeschlimann
Paul Bulpitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orthogene Inc
Original Assignee
Orthogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogene Inc filed Critical Orthogene Inc
Priority to US11/706,922 priority Critical patent/US20070149441A1/en
Publication of US20070149441A1 publication Critical patent/US20070149441A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068General culture methods using substrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/70Polysaccharides
    • C12N2533/80Hyaluronan

Definitions

  • This invention is directed to biomaterials for spatially and temporally controlled delivery of bioactive agents such as drugs, growth factors, cytokines or cells.
  • this invention teaches versatile methods for chemical crosslinking of high molecular weight hyaluronic acid under physiological conditions in situ, to form polymerizable biodegradable materials.
  • the methods are based on the introduction of functional groups into hyaluronic-acid (HA) via formation of an active ester at the carboxylate of the glucuronic acid moiety as an intermediate and subsequent substitution with a side chain containing a nucleophilic group on one end and a (protected) functional group on the other end.
  • the introduced functional groups allow for crosslinking of the HA derivatives.
  • Crosslinked hyaluronic acid hydrogels of this invention are useful in various surgical applications and as a temporary scaffold for tissue regeneration, e.g., in cartilage repair.
  • Chondrocytes may be obtained from a low-loaded area of a joint and proliferated in culture (see Grande; Brittberg; Shortkroff, supra), or mesenchymal stem cells may be harvested, e.g., from the iliac crest marrow, and induced to differentiate along the chondrocyte lineage using growth factors (Harada et al., Bone 9, 177-183 (1988); Wakitani et al., J. Bone Joint Surg. 76-A, 579-592 (1994)).
  • the chondrocyte transplantation procedures currently attempted clinically, although promising, are hampered because technically they are very challenging, the cell preparation is very expensive, and the potential patient pool is limited by age, defect location, history of disease, etc.
  • a second approach is aimed at the recruitment of mesenchymal stem cells from the surrounding connective tissue, e.g., synovium, using chemotactic and/or mitogenic factors (Hunziker and Rosenberg, J. Bone Joint Surg. 78-A, 721-733 (1996); see also U.S. Pat. No. 5,368,858).
  • chemotactic and/or mitogenic factors Hunziker and Rosenberg, J. Bone Joint Surg. 78-A, 721-733 (1996); see also U.S. Pat. No. 5,368,858.
  • the availability of growth factors and cytokines in recombinant form and the lack of complicated cell transplantation make this procedure a very attractive alternative.
  • the shortcoming of both procedures is the difficulty to stably anchor the repair-inducing factors, whether tissue grafts, cells, or growth factors, within the defect site.
  • Hyaluronic acid is unique among glycosaminoglycans in that it is not covalently bound to a polypeptide. HA is also unique in having a relatively simple structure of repeating nonsulfated disaccharide units composed of D-glucuronic acid (GIcUA) and N-acetyl-D-glucosamine (GIcNAc) (Scott et al., The Chemistry. Biology and Medical Applications of Hyaluronan and Its Derivatives , T. C. Laurent (ed.), Portland Press, London, (hereinafter “ Hyaluronan and Its Derivatives ”), pp. 7-15 (1998)). Its molecular mass is typically several million Daltons. HA is also referred to as hyaluronan or hyaluronate, and exists in several salt forms (see formula I).
  • HA is an abundant component of cartilage and plays a key structural role in the organization of the cartilage extracellular matrix as an organizing structure for the assembly of aggrecan, the large cartilage proteoglycan (Laurent and Fraser, FASEB J. 6, 2397-2404 (1992); Morgelin et al., Biophys. Chem. 50, 113-128 (1994)).
  • the noncovalent interactions of aggrecan and link protein with HA lead to the assembly of a large number of aggrecan molecules along the HA-chain and mediate retention of aggrecan in the tissue.
  • the highly negatively charged aggrecan/HA assemblies are largely responsible for the viscoelastic properties of cartilage by immobilizing water molecules.
  • a number of cell surface receptors for HA have been described and shown to play a critical role in the assembly of the pericellular matrix of chondrocytes and other cells, e.g., isoforms of CD44 and vertebrate homologues of Cdc37 (Knudson and Knudson, FASEB J. 7, 1233-1241 (1993); Grammatikakis et al., J. Biol. Chem. 270, 16198-16205 (1995)), or to be involved in receptor-mediated endocytosis and degradation of HA to control HA levels in tissues and body fluids (Laurent and Fraser, supra; Fraser et al., Hyaluronan and Its Derivatives , pp. 85-92 (1998)).
  • HA and its salts are currently being used in therapy for arthropathies by intraarticular injection (Strachnan et al., Ann. Rheum. Dis. 49, 949-952 (1990); Adams, Hyaluronan and Its Derivatives , pp. 243-253 (1998)), in opthalmic surgery for intraocular lens implantation (Denlinger, Hyaluronan and Its Derivatives , pp.
  • modified HA molecules show altered physical characteristics such as decreased solubility in water and/or the chemical reaction strategies used are not designed for crosslinking of HA under physiological conditions (in an aqueous environment, at pH 6.5-8.0).
  • polyaldehydes can be generated by oxidizing sugars using periodate (Wong, CRC Press, Inc., Boca Rayton, Fla., pp. 27 (1993); European Patent No. 9615888).
  • Periodate treatment oxidizes the proximal hydroxyl groups (at C2 and C3 carbons of glucuronic acid moiety) to aldehydes thereby opening the sugar ring to form a linear chain (Scheme 1).
  • periodate oxidation allows for the formation of a large number of functional groups, the disadvantage is the loss of the native backbone structure. Consequently, the generated derivative may not be recognized as HA by cells.
  • hydrogels formed by using periodate oxidized HA as a crosslinker e.g., in combination with the HA-amines described herein, showed very limited tissue transformation and poor cellular infiltration in the rat ectopic bone formation model ( FIG. 6 ). This is in sharp contrast to the HA-aldehyde derivatives described herein.
  • HA derivatives and methodology for in situ polymerization thereof to provide a biodegradable scaffold for tissue regeneration.
  • the HA materials can be polymerized in the presence of cells to serve as a vehicle for cell transplantation.
  • Biomaterials for spatially and temporally controlled delivery of bioactive agents such as drugs, growth factors, cytokines or cells, are a key factor for tissue repair.
  • in situ polymerizable biodegradable materials are needed for cartilage resurfacing that are designed to withstand the mechanical forces in a joint.
  • hydrogels with modified hyaluronic acid and bifunctional crosslinkers or mixtures of hyaluronic acid carrying different functionalities using active ester- or aldehyde-mediated reactions Physical and chemical properties of the hydrogels of this invention were evaluated using biomechanical testing, and by assaying sensitivity towards degradation by glycosidases such as testicular hyaluronidase. Biocompatibility was evaluated using cell culture assays and subcutaneous implantation of the hyaluronic acid materials in rats.
  • This in vivo assay is also the established model for induction of ectopic bone formation by members of the transforming growth factor ⁇ family (TGF- ⁇ ), and several crosslinked hyaluronic acid materials of this invention gave excellent ectopic bone formation in vivo when loaded with appropriate growth factor(s).
  • TGF- ⁇ transforming growth factor ⁇ family
  • compositions of the invention have many therapeutic uses.
  • compositions of the invention may be used to stem hemorrhage in general surgery, reconstruct nerves and vessels in reconstructive, neuro- and plastic surgery, and to anchor skin, vascular, or cartilage transplants or grafts in orthopedic, vascular, and plastic surgery.
  • Compositions of the invention are also useful as vehicles for the delivery of cells or bioactive molecules such as growth factors to stimulate focal repair. Local delivery of growth factors facilitates wound healing and tissue regeneration in many situations, not only in promoting bone formation and stimulating-cartilage repair in orthopedic procedures, but also, e.g., in treating pathological wound conditions such as chronic ulcers.
  • compositions may also serve as a scaffold to generate artificial tissues through proliferation of autologous cells in culture.
  • the anti-adhesive property of some compositions with respect to cells render such compositions particularly suitable to generate tissue separations and to prevent adhesions following surgery.
  • the viscoelastic properties of HA make it particularly well suited for this purpose, and it is used clinically to achieve temporal pain relief by repeated intraarticular injections in arthropathies as a “joint lubricant”, as a protective agent for eye irritations and in ophthalmic surgery, as a barrier to cells in facial and other reconstructions in plastic surgery and dentistry, in reconstructive surgery of tendons, in surgical procedures in the urogenital system, and in thoracic surgery.
  • compositions of the invention also renders them suitable for tissue augmentation in plastic surgery, where the HA matrix serves primarily as an inert biocompatible filler material (Balasz and Laurent, Hyaluronan and Its Derivatives , pp. 325-326 (1998)), e.g., for filling dermal creases or lip reconstruction.
  • HA matrix serves primarily as an inert biocompatible filler material (Balasz and Laurent, Hyaluronan and Its Derivatives , pp. 325-326 (1998)), e.g., for filling dermal creases or lip reconstruction.
  • HA hydrogels match several of the desired properties for a biodegradable material biocompatible with cells.
  • the relatively simple repetitive structure of HA allows for specific modification and introduction of a large number of functional groups, for crosslinking to generate hydrogels with excellent physical properties.
  • HA hydrogels have also successfully been used as a delivery vehicle in chondrocyte transplantation studies (Robinson et al., Calcif. Tissue Int. 46, 246-253 (1990)) and HA has proven its biocompatibility in various forms in clinical practice (for review see Laurent and Fraser, supra; Balazs and Laurent, supra).
  • FIG. 1 shows the results of a ninhydrin test after reductive alkylation of HA and HA-aldehyde in the presence of putrescine. Reductive alkylation was carried out with an excess of putrescine in the presence of pyridine borane. HA or derivatives thereof were purified by repeated ethanol precipitation prior to detection of free amino groups on the HA chain by using the ninhydrin test (Sheng et al., Anal. Biochem. 211, 242-249 (1993)).
  • FIG. 2 shows 1 H NMR of native HA ( FIG. 2A ) and an HA-derivative with protected aldehyde functionality ( FIG. 2B ) in D 2 O at 300 Mhz. Peaks are assigned as indicated on the structural formula.
  • FIG. 3 shows 1 H NMR of HA-derivatives with amine functionality formed from putrescine ( FIG. 3A ), histidine ( FIG. 3B ), lysine ( FIG. 3C ), and adipic dihydrazide ( FIG. 3D ) in D 1 O at 300 Mhz. Peaks are assigned as indicated on the structural formula.
  • FIG. 4 shows digestion of crosslinked HA hydrogels with hyaluronidase.
  • HA-hydrogels were formed by crosslinking 12 mg/ml highly modified ( ⁇ 65-70%) HA-amine (adipic dihydrazido-HA) with 15 mg/ml (SPA) 2 -PEG. Gels were incubated with different concentrations of bovine testicular hyaluronidase for the indicated time and the degradation of the gels was measured by the release of glucuronic acid into the supernatant using the carbazole method (Bitter and Muir, Anal Biochem. 4, 330-334 (1962)).
  • FIG. 4A HA-hydrogels were formed by crosslinking 12 mg/ml highly modified ( ⁇ 65-70%) HA-amine (adipic dihydrazido-HA) with 15 mg/ml (SPA) 2 -PEG. Gels were incubated with different concentrations of bovine testicular hyaluronidase
  • HA-hydrogels were formed by crosslinking 12 mg/ml optimally modified ( ⁇ 20-25%) HA-amine (adipic dihydrazido-HA) with 15 mg/ml (SPA) 2 -PEG ( ⁇ ); 12 mg/ml highly modified ( ⁇ 65-70%) adipic dihydrazido-HA with 15 mg/ml (SPA) 2 -PEG ( ⁇ ); 12 mg/ml optimally modified ( ⁇ 20-25%) lysine methylester-HA with either 15 mg/ml (SPA) 2 -PEG ( ⁇ ) or 0.44 mg/ml glutaraldehyde ( ⁇ ), and 12 mg/ml optimally modified ( ⁇ 10-15%) diaminobutyl-HA with 15 mg/ml (SPA) 2 -PEG (o). Gels were incubated with different concentrations of bovine testicular hyaluronidase for the indicated time and the degradation of the gels was measured as in FIG. 4A above.
  • FIG. 5 shows phase contrast images of cells cultured on different crosslinked HA hydrogels.
  • FIG. 5A Dedifferentiated chondrocytes cultured on a hydrogel formed from highly modified ( ⁇ 65-70%) HA-amine (adipic dihydrazido-HA) crosslinked with 5 mg/ml (SPA) 2 -PEG aggregate as a consequence of inability to adhere to substratum.
  • FIG. 5B Cells cultured on a hydrogel made up by the same HA-amine crosslinked with 0.25 mg/ml glutaraldehyde show a rounded morphology and no aggregation indicating that they are able to adhere to the substratum.
  • FIG. 5A Dedifferentiated chondrocytes cultured on a hydrogel formed from highly modified ( ⁇ 65-70%) HA-amine (adipic dihydrazido-HA) crosslinked with 5 mg/ml (SPA) 2 -PEG aggregate as a consequence of inability to adhere to substra
  • 5C Cells cultured on a hydrogel formed from the HA-amine (adipic dihydrazido-HA) modified to a degree of ⁇ 20-25% and crosslinked with 2 mg/ml (SPA) 2 -PEG adhere to the substratum, spread and subsequently infiltrate the hydrogel. All images show cells 24 h post seeding but morphology remains the same even after several days in culture.
  • HA-amine adipic dihydrazido-HA
  • SPA 2 mg/ml
  • FIG. 6 shows in vivo evaluation of HA hydrogels formed from different HA derivatives using aldehyde-mediated crosslinking.
  • Subcutaneous implantation in rats of HA hydrogels consisting of ( FIG. 6A ) 12 mg/mn optimally modified ( ⁇ 20-25%) HA-amine (adipic dihydrazido-HA) crosslinked with 0.25 mg/ml glutaraldehyde, ( FIG. 6B ) 7 mg/ml of the same HA-amine crosslinked with 7 mg/ml HA-aldehyde (periodate oxidized), ( FIG.
  • FIG. 6C 7 mg/ml of the same HA-amine crosslinked with 7 mg/ml HA-aldehyde (deprotected amino-dimethyl acetal-HA, ⁇ 10-15% modified), or ( FIG. 6D ) 7 mg/ml of the same HA-amine crosslinked with 7 mg/ml HA-aldehyde (deprotected hydrazido-dimethyl acetal-HA, ⁇ 40-45% modified).
  • the hydrogels also contained 1 mg/ml prefibrillized intact collagen type I, 200 ⁇ g/ml BMP-2 and 500 ng/ml IGF-1 to induce bone formation.
  • Tissue specimens were harvested 10 days post implantation, fixed in formalin and processed for histology by paraffin embedding. Sections were stained with Haematoxylin/Eosin. mn, matrix material (note: matrix material shrinks during dehydration); s, skin (indicates orientation of implant).
  • FIG. 7 shows in vivo evaluation of HA hydrogels crosslinked with different NHS-esters.
  • Subcutaneous implantation in rats of HA hydrogels consisting of ( FIG. 7A ) 12 mg/ml highly modified ( ⁇ 65-70%) HA-amine (adipic dihydrazido-HA) crosslinked with 15 mg/nl (SPA) 2 -PEG, ( FIG. 7B ) 12 mg/ml optimally modified ( ⁇ 20-25%) HA-amine (adipic dihydrazido-HA) crosslinked with 15 mg/ml SPA 2 -PEG, or ( FIG.
  • the hydrogels also contained 1 mg/ml prefibrillized intact collagen type I, 200 ⁇ g/ml BMP-2 and 50 ng/ml TGF- ⁇ 2 to induce bone formation.
  • Tissue specimens were harvested 10 days post implantation, fixed in formalin and processed for histology by paraffin embedding. Sections were stained with Haematoxylin/Eosin. m, matrix material (note: matrix material shrinks during dehydration); s, skin (indicates orientation of implant).
  • FIG. 8 shows differential effect of growth factors incorporated into HA hydrogels on tissue transformation.
  • the hydrogels also contained 1 mg/ml prefibrillized intact collagen type I, and were supplemented either with 200 ⁇ g/ml BMP-2 and 500 ng/ml IGF-1 ( FIG. 8A ), or 200 ⁇ g/ml BMP-2 and 50 ng/ml TGF- ⁇ 2 ( FIG. 8B ).
  • Tissue specimens were harvested 10 days post implantation, fixed in formalin and processed for histology by paraffin embedding. Sections were stained with Haematoxylin/Eosin.
  • Scheme 1 illustrates periodate oxidation of hyaluronic acid.
  • Scheme 2 illustrates coupling of amines to hyaluronic acid with EDC via an active triazole ester intermediate.
  • Scheme 3 illustrates coupling of amines to hyaluronic acid with EDC via an active N-hydroxysuccinimde ester intermediate.
  • Scheme 4 illustrates crosslinking of amnine functionalized hyaluronic acid with various bifunctional N-hydroxysuccinimde ester crosslinkers to form hydrogels.
  • SPA SPA 2 -PEG; 2. DTSSP.
  • Scheme 5 illustrates crosslinking of amine functionalized hyaluronic acid with glutaraldehyde to form hydrogels.
  • glutaraldehyde is also known to undergo polymerization by aldol condensation yielding polymers with ⁇ , ⁇ -unsaturated aldehydes at neutral or slightly alkaline pH (Richards and Knowles, J. Mol. Biol. 37, 231-233 (1968)).
  • nucleophilic addition of amines at the ethylenyl double bond creates a stable crosslink.
  • Scheme 6 illustrates formation of hydrogels with aldehyde functionalized hyaluronic acid. (1. amine functionalized HA; 2. bifunctional amine)
  • HA behaves like a hydrogel in an aqueous media even in the absence of crosslinks because it forms a network stabilized by hydrogen bonds and van der Waals forces (Laurent and Fraser, supra).
  • Direct carbodiimide-mediated coupling of amines to the carboxyl group of HA in an aqueous environment e.g., with EDC (1-ethyl-3-[3-dimethylarninopropyl]carbodiimide)
  • EDC 1-ethyl-3-[3-dimethylarninopropyl]carbodiimide
  • HA is soluble in H 2 O or other aprotic polar solvents in native form and when prepared as a sodium salt or when prepared as a tetrabutylammonium salt as described in U.S. Pat. No. 4,957,744, respectively.
  • Simple primary amines e.g., putrescine, which typically have pKa values>9 do not form significant amounts of adduct under acidic coupling conditions.
  • the N-hydroxysulfosuccinimide-derived intermediate allows for the coupling reaction to be carried out at neutral pH (about 7.0 to 8.5) and consequently yields products by reaction with simple primary amines (Scheme 3).
  • R and R′ are alkyl, aryl, alkylaryl or arylalkyl side chains which may contain hetero atoms such as oxygen, nitrogen, and sulfur.
  • the side chain may be branched or unbranched, and be saturated or may contain one or more multiple bonds.
  • the carbon atoms of the side chain may be continuous or may be separated by one or more functional groups such as an oxygen atom, a keto group, an amino group, an oxycarbonyl group, etc.
  • the side chain may be substituted with aryl moieties or halogen atoms, or may in whole or in part be formed by ring structures such as cyclopentyl, cyclohexyl, cycloheptyl, etc.
  • the side chain may have a terminal functional group for crosslinking such as aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, etc.
  • the side chain may be a bioactive peptide, e.g., containing receptor binding sites, crosslinking sites for transglutarninases, or proteolytic cleavage sites.
  • Terminal functional groups of the side chain useful for crosslinking of HA under physiological conditions may be selected from the following list:
  • Arylazides e.g., 4-(p-azidosalicylamido)butylamine
  • sulfhydryls e.g., S-methylsulfide cysteine H 2 N—R—SH (XI)
  • Peptides e.g., H 2 N-APQQEA, comprising substrate sites for enzymatic crosslinking, e.g., by transglutarninases (Parameswaran et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8472-8475 (1990); Hohenadl et al., J. Biol. Chem. 270, 23415-23420 (1995)).
  • the carbodiimides useful in this reaction may be represented by the following formula: R—N ⁇ C ⁇ N—R′ (XII) wherein R and R′ comprise side chains of variable structure as described above in detail. Carbodiimides which are soluble in an aqueous media are preferred.
  • the active ester may be of the following class and be formed by carbodiimide-mediated coupling of a compound for preparation of these active esters known to a person in the art:
  • Triazole Esters e.g. 1-hydroxybenzotriazole
  • a side chain containing a protected aldehyde in the form of an acetal was prepared as follows. N-(2,2-dimethoxyethyl)-4-(methoxycarbonyl)butanamide was obtained from aminoacet-aldehyde dimethyl acetal and mono-methyl succinate using EDC coupling. An amino group for the coupling to HA was subsequently introduced by reacting the product with hydrazine, yielding the desired side chain with the protected aldehyde, N-(2,2-dimethoxyethyl)-4-(hydrazido)butanamide. The side chain was coupled to HA using HOBT and EDC (Scheme 2).
  • Diaminoethane, lysine methyl ester, histidine, and adipic, succinic or suberic dihydrazide was coupled to HA using HOBT and EDC (up to 5-fold excess depending on the desired degree of modification) and adjusting the pH to ⁇ 6.5 by repeated addition of 0.1M HCl during the reaction (Scheme 2).
  • HA-derivatives were also prepared in a similar manner using N-hydroxysulfosuccinimide and primary amines containing unconjugated amino groups with a higher pKa (>9) such as 1,4-diaminobutane or 1,6 diaminohexane (Scheme 3).
  • the HA derivatives were purified by repeated ethanol precipitation and by extensive dialysis, and the nature of the HA derivatives was confirmed by 1 H NMR ( FIG. 3 ).
  • the degree of modification was calculated from the NMR data and found to be as high as 70%. Reaction conditions were subsequently adjusted such that a degree of modification of approximately 20% was achieved. Limiting the amount of carbodiimide proved to be most successful in controlling the degree of modification.
  • a degree of modification of 10-25% yielded efficient crosslinking but also a molecule that would still be recognized by glycosidases and by HA receptors as HA and thus allow for recognition and processing of the material by cells (see below).
  • the functionalized HA molecules can be crosslinked by reacting HA derivatives with different functionalities or using homo- or heterobifunctional crosslinkers which are available in large variety.
  • the following basic reaction schemes are suitable for crosslinking of the described forms of modified HA (see Examples 9-12):
  • HA-amine derivatives Mr ⁇ 10 6
  • bifunctional active esters e.g. polyethyleneglycol-bis-succinimnidyl-propionate [(SPA) 2 -PEG] and reducible 3,3′-dithiobis(sulfo-succinimidyl-propionate) (DTSSP) (Scheme 4), or bifunctional aldehydes, e.g. glutaraldehyde (Scheme 5), generated excellent hydrogels.
  • Stable gels could be formed by crosslinking 5 to 25 mg/ml HA derivative with >0.05 mM aldehyde or >0.2 mM active ester (numbers are reflecting functional group concentrations).
  • Optimal gels were generated by crosslinking 10-15mg/ml HA derivative, modified to a degree of about 10-25%, with about 0.2 mM aldehyde or 0.6 mM active ester.
  • crosslinking of the HA-aldehyde derivatives (Mr ⁇ 10 6 ) (optimally about 10-15 mg/ml) with bifunctional amines (optimally about 0.2 mM) yielded excellent gels (Scheme 6).
  • Conjugated amines such as dihydrazines or benzylamines are required for in situ polymerization of HA in this case to resonance stabilize the instable Schiff base product formed by reaction of an aldehyde with a primary amine (i.e.
  • Hydrogels were also formed from an equimolar mixture of HA-aldehyde derivatives and the different HA-amine derivatives (Scheme 6). Optimal gels were formed with ⁇ 15 mg/ml of the HA derivatives. At the optimal concentrations of HA and crosslinker, gelation occurred typically in about 30 sec. to 5 min. which is suitable for in situ polymerization.
  • the crosslinked HA hydrogels were sensitive to glycosidases, i.e. testicular hyaluronidase, indicating that they are biodegradable ( FIG. 4 ).
  • HA hydrogels with cell adhesion molecules such as fibronectin (in the range of 0.1 to 1 mg/ml) did induce adhesion and spreading of cells on the materials independent of the nature of the crosslinker and the crosslinking density, but did not change the results with regard to cell infiltration, demonstrating that the lack of infiltration is due to the high crosslinking density and not the absence of cell-matrix interactions. See below and FIG. 7 .
  • cell adhesion molecules such as fibronectin
  • Subcutaneous implantation of biomaterials in rats is the established model for evaluation of biocompatibility of biomaterials (Laurencin et al., J. Biomed. Mat. Res. 24, 1463-1481 (1990)) and for induction of ectopic bone formation by members of the TGF- ⁇ gene family, and bone morphogenetic proteins (BMP) in particular (Wang et al., Proc. Natl. Acad. Sci. U.S.A. 87, 2220-2224 (1990); Sampath et al., J. Biol. Chem. 267, 20352-20362 (1992)). Taking into consideration the cell culture results, we have formulated a number of HA hydrogels for in vivo biocompatibility testing in this model.
  • FIGS. 6 and 7 Implantation of prepolymerized HA hydrogel discs loaded with recombinant BMP-2 and IGF-1 or TGF- ⁇ 2 subcutaneously in rats showed a mild fibrosis with a varying degree of cartilage and bone formation depending on the nature of the HA biomaterial ( FIGS. 6 and 7 ).
  • the growth factors were mixed with the HA derivatives prior to gelling and the induction of bone formation suggests that neither reaction mechanism used for HA crosslinking (aldehyde or active ester-mediated reactions) significantly affected the biological activity of the growth factors. Little inflammation was observed with active ester crosslinked HA-amine derivatives ( FIG. 7 ) or with HA-amine derivatives crosslinked with various HA-aldehyde derivatives ( FIGS.
  • the infiltration and transformation rate was similar with BMP-2/IGF-1 and BMP-2/TGF- ⁇ 2 loaded biomaterials, indicating that the resorption rate is a material property.
  • the newly formed tissue was largely cartilage in the first group and largely bone in the second group ( FIG. 8 ), exemplifying the angiogenic effect of TGF- ⁇ 2 (Yang and Moses, J. Cell. Biol., 111, 731-741 (1990)).
  • This demonstrates that the biological activity of the HA material can be modulated by inclusion of different bioactive factors.
  • the lack of significant adverse effects and the demonstration of the desired biological activity of these novel HA biomaterials in vivo demonstrates their usefulness as a delivery vehicle for cells and growth factors in the field of tissue regeneration.
  • HA a virus that has been used for the production of HA.
  • Extraction from tissue typically uses fresh or frozen cocks' combs (U.S. Pat. No. 5,336,767), although other tissues including the synovial fluid of joints (Kvam et al., Anal. Biochem. 211, 44-49 (1993)), human umbilical cord tissue, bovine vitreous humor, and bovine tracheae, have been used.
  • the HA raw material for preparing the compositions of the invention preferably consists of high molecular weight HA, more preferably of molecular weight greater than 0.5 million daltons, and more preferably of molecular weight greater than one million daltons.
  • the HA raw material for the compositions of examples of this invention described herein was obtained from Genzyme Corp. (Cambridge, Mass.), and had a molecular weight greater than one million daltons. The size of the HA was unchanged after derivatization.
  • compositions of the invention have many therapeutic uses.
  • the fact that the compositions may be cured in a surgically practical time frame of one to five minutes in situ with concurrent crosslinking to the tissue surfaces allows for employment as a tissue glue.
  • Many situations in various surgical applications require such adhesives.
  • the compositions of the invention may be used to stem hemorrhage in general surgery, reconstruct nerves and vessels in reconstructive, neuro- and plastic surgery, and to anchor skin, vascular, or cartilage transplants or grafts in orthopedic, vascular, and plastic surgery.
  • HA which affects the crosslinking density of the material and interaction with cellular proteins, including receptors and glycosidases
  • concentration of the crosslinker which affects the crosslinking density of the material
  • size of the generated cross-bridge which affects the pore size of the material
  • nature of the crosslinking mechanism which determines polymerization time and the specificity of the reaction
  • (5) the nature of the cross-bridge which provides biological cues. See FIGS. 4, 5 , and 7 for data concerning HA hydrogels with different crosslinking densities and pore sizes.
  • active ester- or photo-crosslinking are preferred to form materials for applications requiring fast gelation and strong bonding with tissue surfaces, such as tissue glues.
  • Materials with anti-adhesive properties which are useful to form tissue separations or for tissue augmentation, are formed from highly modified HA derivatives with low molecular weight crosslinkers, which generates a dense material with very small pores, thereby minimizing cell adhesion and infiltration.
  • biodegradable scaffolds for tissue repair are formed from HA with a limited degree of derivativization and high molecular weight crosslinkers, which generate a porous, biodegradable material.
  • the crossbridge may even contain biological cues, such as peptide sequences, which facilitate material degradation by, for example, proteolysis or cellular infiltration (e.g., the RGD sequence).
  • compositions of this invention were designed to serve as a vehicle for the delivery of cells or bioactive molecules such as growth factors to stimulate focal repair.
  • the crosslinked HA derivatives are porous hydrogels in which biologically or therapeutically active compounds (e.g., growth factors, cytokines, drugs, and the like) can be physically or chemically incorporated. These compounds will then be subject to sustained release by chemical, enzymatic, and physical erosion of the hydrogel and/or the covalent linkage between the HA chain and biologically active compound over a period of time. Local delivery of growth factors with such a scaffold facilitates wound healing and tissue regeneration in many situations.
  • biologically or therapeutically active compounds e.g., growth factors, cytokines, drugs, and the like
  • compositions of the invention may be used not only to promote bone formation and stimulate cartilage repair in orthopedic procedures, as described more fully below, but also to treat pathological wound conditions such as chronic ulcers. They may also serve as a scaffold to generate artificial tissues, e.g., cartilage (Hauselmann et al., Am. J. Physiol. 271, C742-752 (1996)), through proliferation of autologous cells in culture. Similar procedures for generation of equivalents of other tissues or organs, including skin, liver, and others, in culture may be developed in the future and may be used in combination with the compositions of the invention.
  • cartilage Heauselmann et al., Am. J. Physiol. 271, C742-752 (1996)
  • Similar procedures for generation of equivalents of other tissues or organs, including skin, liver, and others, in culture may be developed in the future and may be used in combination with the compositions of the invention.
  • Highly crosslinked materials have an anti-adhesive property with respect to cells, and such compositions may be used to generate tissue separations and to prevent adhesions following surgery. See FIGS. 5A and 7C , showing highly modified HA-amine, i.e., adipic dihyrazido HA, preferably crosslinked with low molecular weight bifunctional NHS-ester.
  • the viscoelastic properties of HA make it particularly well suited for this purpose, and it is used clinically to achieve temporal pain relief by repeated intraarticular injections in arthropathies as a “joint lubricant”, and as a protective agent for eye irritations and in ophthalmic surgery.
  • the technique of tissue separation is used in facial reconstruction in plastic surgery and dentistry.
  • compositions of the invention also renders them suitable for tissue augmentation in plastic surgery, where the HA matrix serves primarily as a biocompatible filler material, e.g., for filling dermal creases or lip reconstruction.
  • a biocompatible filler material e.g., for filling dermal creases or lip reconstruction.
  • HA hydroxyapatitin
  • the half-life of pharmacological compounds, both synthetic and biological, has been shown to be drastically increased when delivered in a form conjugated to HA (Larsen and Balazs, Adv. Drug Delivery Rev. 7, 279-293 (1991), Drobnik, J., Drug Delivery Rev. 7, 295-308 (1991)).
  • the functionalized forms of HA provided by this invention allow for easy substitution with pharmacologically active agents, such as anti-inflammatories, analgesics, steroids, cardiovascular agents, anti-tumor agents, immunosuppressants, sedatives, anti-bacterial, anti-fungal, and anti-viral agents, etc., and may be used for sustained drug release over time, either locally in hydrogel form or systemically in free form.
  • pharmacologically active agents such as anti-inflammatories, analgesics, steroids, cardiovascular agents, anti-tumor agents, immunosuppressants, sedatives, anti-bacterial, anti-fungal, and
  • the functionalized forms of HA of this invention have applications as a tissue glue or bioactive matrix material in the treatment of chondral and osteochondral fractures, osteochondritis dissecans, meniscal tears, as well as ruptured ligaments, tendons, or myotendineous junctions.
  • the HA materials of this invention may serve to facilitate anchorage of chondral or osteochondral transplants or grafts, or other biological or artificial implant materials, or to stimulate new bone or cartilage formation by serving as a scaffold for cells or as a delivery vehicle for growth factors.
  • One general approach to promote articular cartilage repair based on the compositions of the invention comprises using: (1) in situ polymerized HA hydrogel as a matrix to fill the defect which is to be repaired and to provide a scaffold for repair cells, (2) an optional chemotactic agent to attract repair cells to the matrix and defect site, or alternatively, autologous chondrocytes or mesenchymal stem cells, (3) an optional factor to promote cellular proliferation of repair cells in the matrix and defect site; (4) sustained release of a transforming factor by the HA hydrogel over time to promote differentiation of the repair cells into chondrocytes which produce new cartilage; and (5) an optional anti-angiogenic factor to prevent vascularization and endochondral ossification of the newly formed cartilage.
  • suitable factors are known to those skilled in the art, and may be found in, e.g., U.S. Pat. No. 5,368,858.
  • HA hydrogels Delivery of growth factors in active form may require supplementation of the HA hydrogels with additional ingredients, such as growth factor binding molecules like heparin and collagen.
  • additional ingredients such as growth factor binding molecules like heparin and collagen.
  • crosslinked hyaluronic acid hydrogels that are rapidly infiltrated by cells such as those formed from an HA-amine derivative crosslinked with a polyvalent high molecular weight NHS-ester crosslinker, e.g., (SPAs-PEG, are selected which are resorbed and replaced by repair tissue within about 2 to 3 weeks.
  • cells and/or growth factors may be mixed in prior to gelling.
  • the pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution.
  • HA was precipitated by addition of three volume equivalents of ethanol.
  • the precipitate was redissolved in H 2 O at a concentration of approximately 5 mg/ml and the precipitation repeated twice.
  • the purified product was freeze dried and kept at 4° C. under N 2 . See FIG. 2B for NMR data of the product.
  • HA-acetals to form HA-aldehydes The acetal modified HA(formula XII) was dissolved in H 2 O to a concentration of 5-10 mg/ml and 1M HCl was added to give a final concentration of 0.025M. The solution was then allowed to stand at room temperature for 0.5 to 1.0 h. The solution was neutralized by the addition of 1M NaOH, yielding the deprotected HA-aldehyde (formula XXII). HA—CO—R—CH(OCH 3 ) 2 (XXI) ⁇ HA—CO—R—CHO (XXII)
  • Diaminoethane-HA (formula XXIII)—Sodium hyaluronate (100 mg, 0.25 mmol) and 1,2-diaminoethane HCl (0.998 g, 7.5 mmol) was dissolved in H 2 O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution.
  • HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H 2 O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N 2 .
  • L-Lysine methyl ester-HA (formula XXIV)—Sodium hyaluronate (100 mg, 0.25 mmol) and L-lysine methyl ester dihydrochloride (1.748 g, 7.5 mmol) was dissolved in H 2 O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution.
  • HA was precipitated by addition of three volume equivalents of ethanol.
  • the precipitate was redissolved in H 2 O at a concentration of approximately 5 mg/ml and the precipitation repeated twice.
  • the purified product was freeze dried and kept at 4° C. under N 2 . See FIG. 3C for NMR data of the product.
  • L-Histidine methyl ester HA (formula XXV)—Sodium hyaluronate (100 mg, 0.25 mmol) and L-histidine methyl ester dihydrochloride (1.815 g, 7.5 mmol) was dissolved in H 2 O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT(169 mg, 1.25 mmol) predissolved in a 1:1 mixture of H 2 O and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution.
  • HA was precipitated by addition of three volume equivalents of ethanol.
  • the precipitate was redissolved in H 2 O at a concentration of approximately 5 mg/ml and the precipitation repeated twice.
  • the purified product was freeze dried and kept at 4° C. under N 2 . See FIG. 3B for NMR data of the product.
  • Hydrazido-HA (formula XXVI)—Sodium hyaluronate (100 mg, 0.25 mmol) and dihydrazide i.e. adipic dihydrazide (1.31 g, 7.5 mmol) was dissolved in H 2 O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1 M NaOH and NaCl added to produce a 5% w/v solution.
  • HA was precipitated by addition of three volume equivalents of ethanol.
  • the precipitate was redissolved in H 2 O at a concentration of approximately 5 mg/ml and the precipitation repeated twice.
  • the purified product was freeze dried and kept at 4° C. under N 2 . See FIG. 3D for NMR data of the product.
  • Diaminoalkyl-HA (formula XXVII)—Sodium hyaluronate (100 mg, 0.25 mmol) and a diaminoalkane, i.e. 1,2-diaminobutane HCl (1.208 g, 7.5 mmol) was dissolved in H 2 O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 7.5 and NHS.S0 3 Na (268 mg, 1.25 mmol) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCG added to produce a 5% w/v solution.
  • HA was precipitated by addition of three volume equivalents of ethanol.
  • the precipitate was redissolved in H 2 O at a concentration of approximately 5 mg/ml and the precipitation repeated twice.
  • the purified product was freeze dried and kept at 4° C. under N 2 . See FIG. 3A for NMR data of the product.
  • crosslinked HA hydrogels The general procedure for forming crosslinked HA hydrogels is as follows: Modified HA is dissolved by agitation in H 2 O or phosphate buffered saline (pH 7.4-8.5) at a concentration of 5-25 mg/ml. The degree of modification of the HA derivative is derived from the integration of the 1 H NMR peaks. After complete dissolution, the HA derivative solution is transferred to a 1 ml syringe. When reacting the HA derivatives with low molecular weight crosslinkers, a slight excess of the compound (about 1.1 molar equivalent of functional groups) is dissolved in a second 1 ml syringe in 1/10 of the HA derivative volume immediately prior to use.
  • the syringes are connected while paying special attention to excluded air, the contents are rapidly mixed, typically with 20 passages, and then extruded.
  • 0.5-1.0 equivalent of HA-aldehyde is mixed with 1 equivalent of HA-hydrazine, depending on the degree of modification of the HA derivatives.
  • gelation occurs within about 30 seconds to several minutes, depending on the formulation, and the gel properties do not significantly change after approximately 5 minutes.
  • HA hydrogels are formed in 1 ml syringes by crosslinking 12 mg/ml HA-amnine in phosphate buffered saline with various crosslinkers as indicated in FIG. 4 . Gelling is allowed to occur for 1 hour at 37° C. for the reaction to be complete, after which identical ⁇ 100 ⁇ l cylindrical gels are formed by cutting the syringes with a razor blade.
  • the gels are incubated with different concentrations of bovine testicular hyaluronidase (Sigma) 50-5000 U/mL in 400 ⁇ l of 30 mM citric acid, 150 mM Na 2 HPO 4 , pH 6.3, 150 mM NaCl for the indicated time 0-48 hours. Degradation of the gels is determined from the release of glucuronic acid into the supernatant as measured using the carbazole method (Bitter and Muir, supra). See FIG. 4 .
  • Crosslinked HA hydrogels as a matrix for cell culture Chodedrocytes were isolated from bovine nose cartilage according to established procedures (Hauselmann et al., Matrix 12, 116-129 (1992; Kuttner et al., J. Cell Biol. 93, 743-750 (1982)), cultured in Ham's F12 medium containing 5% fetal bovine serum and antibiotics, and dedifferentiated by monolayer culture on plastic.
  • cells 2.5 ⁇ 10 5
  • HA hydrogels were polymerized in 24-well plates ( ⁇ 15mm diameter and 3mm height) for 1 h at room temperature, and extensively rinsed with phosphate buffered saline. Cell adhesion molecules or chemotactic factors, e.g. IGF-1, were added to the HA solution prior to crosslinking when desired. After 24 h, cells (2.5 ⁇ 10 5 ) were seeded on top of the HA-hydrogels and cultured as above.
  • gels were fixed in phosphate buffered 4% paraformaldehyde and processed for paraffin embedding. Cell infiltration was assessed by staining sections with Haematoxylin/Eosin. See FIG. 5 .
  • HA hydrogels were polymerized in 3 ml syringes as described.
  • Collagen fibrils were prepared by slow polymerization (from dilute solutions of 2-3 mg/ml) of acid-solubilized couagen in phosphate buffered saline and harvested by centrifugation following standard protocols (McPherson et al., Collagen Rel. Res. 5, 119-135 (1985)). Gelling of the HA hydrogels was allowed to occur for 24 h at room temperature for the reaction to be complete, after which identical ⁇ 3mm thick cylindrical gels were prepared by cutting the syringes with a razor blade. HA hydrogel discs were then placed in each pocket and the skin incisions closed with sutures. Ten days post operatively, the rats were euthanized and the appearance of the implant sites, i.e.

Abstract

Methods for chemical modification of hyaluronic acid, formation of amine or aldehyde functionalized hyaluronic acid, and the cross-linking thereof to form hydrogels are provided. Functionalized hyaluronic acid hydrogels of this invention can be polymerized in situ, are biodegradable, and can serve as a tissue adhesive, a tissue separator, a drug delivery system, a matrix for cell cultures, and a temporary scaffold for tissue regeneration.

Description

    TECHNICAL FIELD OF THE INVENTION
  • This invention is directed to biomaterials for spatially and temporally controlled delivery of bioactive agents such as drugs, growth factors, cytokines or cells. In particular, this invention teaches versatile methods for chemical crosslinking of high molecular weight hyaluronic acid under physiological conditions in situ, to form polymerizable biodegradable materials. The methods are based on the introduction of functional groups into hyaluronic-acid (HA) via formation of an active ester at the carboxylate of the glucuronic acid moiety as an intermediate and subsequent substitution with a side chain containing a nucleophilic group on one end and a (protected) functional group on the other end. The introduced functional groups allow for crosslinking of the HA derivatives. Crosslinked hyaluronic acid hydrogels of this invention are useful in various surgical applications and as a temporary scaffold for tissue regeneration, e.g., in cartilage repair.
  • BACKGROUND OF THE INVENTION
  • Repair of Articular Cartilage
  • The failure of regenerating persistent hyaline cartilage by surgical procedures has prompted investigators to attempt repair using biological strategies. The biological repair of articular cartilage is, with a few exceptions, still at an experimental stage. Biological cartilage repair has been approached in two basic ways. First, autologous chondrocytes have been transplanted into a lesion to induce repair (Grande et al., J. Orthop. Res. 7, 208-214 (1989); Brittberg et al., New EngI. J. Med. 331, 889-895 (1994); Shortkroffet al., Biomaterials 17, 147-154 (1996)). Chondrocytes may be obtained from a low-loaded area of a joint and proliferated in culture (see Grande; Brittberg; Shortkroff, supra), or mesenchymal stem cells may be harvested, e.g., from the iliac crest marrow, and induced to differentiate along the chondrocyte lineage using growth factors (Harada et al., Bone 9, 177-183 (1988); Wakitani et al., J. Bone Joint Surg. 76-A, 579-592 (1994)). The chondrocyte transplantation procedures currently attempted clinically, although promising, are hampered because technically they are very challenging, the cell preparation is very expensive, and the potential patient pool is limited by age, defect location, history of disease, etc. Cells have also been transplanted into cartilage defects in the form of perichondral grafts, e.g., obtained from costal cartilage, but with limited success due to the limit in donor material and the complication of endochondral ossification of the graft site observed in longterm follow-up (Aniel et al., Connect. Tissue Res. 18, 27-39 (1988); O'Driscoll et al., J. Bone Joint Surg. 70-A, 595-606 (1988); Homminga et al., Acta Orthop. Scand. 326-329 (1989); Homminga et al., J. Bone Joint Surg. 72-B, 1003-1007 (1990)). A second approach is aimed at the recruitment of mesenchymal stem cells from the surrounding connective tissue, e.g., synovium, using chemotactic and/or mitogenic factors (Hunziker and Rosenberg, J. Bone Joint Surg. 78-A, 721-733 (1996); see also U.S. Pat. No. 5,368,858). The availability of growth factors and cytokines in recombinant form and the lack of complicated cell transplantation make this procedure a very attractive alternative. The shortcoming of both procedures is the difficulty to stably anchor the repair-inducing factors, whether tissue grafts, cells, or growth factors, within the defect site. Also, outlining of the space that is to be repaired, e.g., by filling it with a matrix material, appears to be crucial to recreate a level cartilage surface (Hunziker and Rosenberg, supra). Thus far, the availability of candidate matrix materials has been the limiting factor, and anchoring of materials seeded with chondrocytes and/or chondrogenic factors difficult, explaining the unsatisfactory results obtained with currently available materials such as polylactic acid and polyglycolic acid scaffolds (Freed et al., J. Biomed. Mat. Res. 28, 891-899 (1994); Chu et al., J. Biomed. Mat. Res. 29, 1147-1154 (1995)); calcium phosphate minerals (Nakahara et al., Clin. Orthop. 276, 291-298 (1992)), fibrin sealants (Itay et al., Clin. Orthop. 220, 284-303 (1987)), and collagen gels (Wakitani et al., J. Bone Joint Surg. 71-B, 74-80 (1989)). We have developed novel biodegradable materials based on hyaluronic acid which are optimized for the biological requirements posed on a repair material in a synovial joint and which allow in situ polymerization.
  • Biology of Hyaluronic Acid and Its Therapeutic Use
  • Hyaluronic acid (HA) is unique among glycosaminoglycans in that it is not covalently bound to a polypeptide. HA is also unique in having a relatively simple structure of repeating nonsulfated disaccharide units composed of D-glucuronic acid (GIcUA) and N-acetyl-D-glucosamine (GIcNAc) (Scott et al., The Chemistry. Biology and Medical Applications of Hyaluronan and Its Derivatives, T. C. Laurent (ed.), Portland Press, London, (hereinafter “Hyaluronan and Its Derivatives”), pp. 7-15 (1998)). Its molecular mass is typically several million Daltons. HA is also referred to as hyaluronan or hyaluronate, and exists in several salt forms (see formula I).
    Figure US20070149441A1-20070628-C00001
  • HA is an abundant component of cartilage and plays a key structural role in the organization of the cartilage extracellular matrix as an organizing structure for the assembly of aggrecan, the large cartilage proteoglycan (Laurent and Fraser, FASEB J. 6, 2397-2404 (1992); Morgelin et al., Biophys. Chem. 50, 113-128 (1994)). The noncovalent interactions of aggrecan and link protein with HA lead to the assembly of a large number of aggrecan molecules along the HA-chain and mediate retention of aggrecan in the tissue. The highly negatively charged aggrecan/HA assemblies are largely responsible for the viscoelastic properties of cartilage by immobilizing water molecules. A number of cell surface receptors for HA have been described and shown to play a critical role in the assembly of the pericellular matrix of chondrocytes and other cells, e.g., isoforms of CD44 and vertebrate homologues of Cdc37 (Knudson and Knudson, FASEB J. 7, 1233-1241 (1993); Grammatikakis et al., J. Biol. Chem. 270, 16198-16205 (1995)), or to be involved in receptor-mediated endocytosis and degradation of HA to control HA levels in tissues and body fluids (Laurent and Fraser, supra; Fraser et al., Hyaluronan and Its Derivatives, pp. 85-92 (1998)). Blocking of the interaction of these receptors with HA in prechondrogenic micromass cultures from embryonic limb bud mesoderm inhibits chondrogenesis, indicating that the establishment and maintainance of a differentiated chondrocyte phenotype is at least in part dependent on HA and HA-receptor interactions (Maleski and Knudson, Exp. Cell. Res. 225, 55-66 (1996)).
  • HA and its salts are currently being used in therapy for arthropathies by intraarticular injection (Strachnan et al., Ann. Rheum. Dis. 49, 949-952 (1990); Adams, Hyaluronan and Its Derivatives, pp. 243-253 (1998)), in opthalmic surgery for intraocular lens implantation (Denlinger, Hyaluronan and Its Derivatives, pp. 235-242 (1998), to promote wound healing in various tissues (King et al., Surgery 109, 76-84 (1991)), or more recently, in derivatized and/or crosslinked form to manufacture thin films which are used for tissue separation (for review see Laurent and Fraser, supra; Weiss, Hyaluronan and Its Derivatives, pp. 255-266 (1998); Larsen, Hyaluronan and Its Derivatives, pp. 267-281 (1998); Band, Hyaluronan and Its Derivatives, pp. 33-42 (1998)). Extensive efforts have been made by various laboratories to produce derivatives of HA with unique properties for specific biomedical applications. Most of the developments have been focusing on the production of materials such as films or sponges for implantation and the substitution of HA with therapeutic agents for delayed release and/or prolonged effect (for review see Band, supra; Prestwich et al., Hyaluronan and Its Derivatives, pp. 43-65 (1998); Gustafson, Hyaluronan and Its Derivatives, pp. 291-304 (1998)). Strategies have included esterification of HA (U.S. Pat. Nos. 4,957,744 and 5,336,767), acrylation of HA (U.S. Pat. No. 5,410,016), and cross-linking of HA using divinyl sulfone (U.S. Pat. No. 4,582,865) or glycidyl ether (U.S. Pat. No. 4,713,448). However, the modified HA molecules show altered physical characteristics such as decreased solubility in water and/or the chemical reaction strategies used are not designed for crosslinking of HA under physiological conditions (in an aqueous environment, at pH 6.5-8.0).
  • It is well known that polyaldehydes can be generated by oxidizing sugars using periodate (Wong, CRC Press, Inc., Boca Rayton, Fla., pp. 27 (1993); European Patent No. 9615888). Periodate treatment oxidizes the proximal hydroxyl groups (at C2 and C3 carbons of glucuronic acid moiety) to aldehydes thereby opening the sugar ring to form a linear chain (Scheme 1). While periodate oxidation allows for the formation of a large number of functional groups, the disadvantage is the loss of the native backbone structure. Consequently, the generated derivative may not be recognized as HA by cells. In fact, hydrogels formed by using periodate oxidized HA as a crosslinker, e.g., in combination with the HA-amines described herein, showed very limited tissue transformation and poor cellular infiltration in the rat ectopic bone formation model (FIG. 6). This is in sharp contrast to the HA-aldehyde derivatives described herein.
  • The introduction of free amino groups on HA, which could be used for further convenient coupling reactions under mild physiological conditions, has been a subject of great interest. Previous methods have produced a free amino group on high molecular weight HA by alkaline N-deacetylation of its glucosamine moiety (Curvall et al., Carbohydr. Res. 41, 235-239 (1975); Dahl et al., Anal. Biochem. 175, 397-407 (1988)). However, concomitant degradations of HA via beta-elimination in the glucuronic acid moiety was observed under the harsh reaction conditions needed. This is of particular concern because low molecular weight HA fragments, in contrast to high molecular weight HA, have been shown to be capable of provoking inflammatory responses (Noble et al., Hyaluronan and Its Derivatives, pp. 219-225 (1998)). An early report claimed that carbodilmide-catalyzed reaction of HA with glycine methyl ester, a monofunctional amine, led to the formation of an amide linkage (Danishefsky and Siskovic, Carbohydr. Res. 16, 199-201 (1971)). This however, has been proven by a number of studies not to be the case (Kuo et al., Bioconjugate Chem. 2, 232-241 (1991); Ogamo et al., Carboh dr. Res. 105, 69-85 (1982)). Under mildly acidic conditions the unstable intermediate O-acylisourea is readily formed, which in the absence of nucleophiles, rearranges by a cyclic electronic displacement to a stable N-acylurea (Kurzer and Douraghi-Zedeh, Chem. Rev. 67, 107-152 (1967)). This O→N migration of the O-acylisourea also occurs when the nucleophile is a primary amine (Kuo et al., supra) and any amide formation that does occur is insignificant as reported by Ogamo et al., supra. Experiments where high molecular weight HA (Mr˜2×10 Da) was reacted with an excess of the fluorescent label 5-aminofluorescine in the presence of the carbodiimide EDC achieved only 0.86% of theoretical labelling. The introduction of a terminal hydrazido group on HA with a variable spacer has recently been achieved and has led to the ability to conduct further coupling and crosslinking reactions (Pouyani and Prestwich, Bioconjugate Chem. 5, 339-347 (1994), U.S. Pat. Nos. 5,616,568, 5,652,347, and 5,502,08 1; Vercruysse et al., Bioconjupate Chem. 8, 686-694 (1997)).
  • It is an objective of this invention to provide a method for more versatile modification of HA with various functional groups that allow for crosslinking of the HA derivatives under physiological conditions. It is another objective that the method of functionalization does not compromise the molecular weight or chemical identity (except of the target carboxyl group for coupling) of HA. It is a further objective that the method of functionalization provides HA molecules that are well tolerated in vivo and are biodegradable.
  • It is also an objective of this invention to identify HA derivatives and methodology for in situ polymerization thereof to provide a biodegradable scaffold for tissue regeneration. It is another objective that the HA materials can be polymerized in the presence of cells to serve as a vehicle for cell transplantation. It is a further objective to provide methodology for functionalization and cross-linking of HA that allows for variations in the biomechanical properties of the formed gels as well as in the sensitivity to cellular infiltration and degradation.
  • SUMMARY OF THE INVENTION
  • Biomaterials for spatially and temporally controlled delivery of bioactive agents such as drugs, growth factors, cytokines or cells, are a key factor for tissue repair. In particular, in situ polymerizable biodegradable materials are needed for cartilage resurfacing that are designed to withstand the mechanical forces in a joint. We have developed a versatile method for chemical crosslinking of high molecular weight hyaluronic acid under physiological conditions. The method is based on the introduction of functional groups into hyaluronic acid by formation of an active ester at the carboxylate of the glucuronic acid moiety and subsequent substitution with a side chain containing a nucleophilic group on one end and a (protected) functional group on the other end. We have formed hyaluronic acid with amino or aldehyde functionality, and formed hydrogels with modified hyaluronic acid and bifunctional crosslinkers or mixtures of hyaluronic acid carrying different functionalities using active ester- or aldehyde-mediated reactions. Physical and chemical properties of the hydrogels of this invention were evaluated using biomechanical testing, and by assaying sensitivity towards degradation by glycosidases such as testicular hyaluronidase. Biocompatibility was evaluated using cell culture assays and subcutaneous implantation of the hyaluronic acid materials in rats. This in vivo assay is also the established model for induction of ectopic bone formation by members of the transforming growth factor β family (TGF-β), and several crosslinked hyaluronic acid materials of this invention gave excellent ectopic bone formation in vivo when loaded with appropriate growth factor(s).
  • As set forth below in the detailed description of the invention, the compositions of the invention have many therapeutic uses. For example, compositions of the invention may be used to stem hemorrhage in general surgery, reconstruct nerves and vessels in reconstructive, neuro- and plastic surgery, and to anchor skin, vascular, or cartilage transplants or grafts in orthopedic, vascular, and plastic surgery. Compositions of the invention are also useful as vehicles for the delivery of cells or bioactive molecules such as growth factors to stimulate focal repair. Local delivery of growth factors facilitates wound healing and tissue regeneration in many situations, not only in promoting bone formation and stimulating-cartilage repair in orthopedic procedures, but also, e.g., in treating pathological wound conditions such as chronic ulcers. These compositions may also serve as a scaffold to generate artificial tissues through proliferation of autologous cells in culture. On the other hand, the anti-adhesive property of some compositions with respect to cells render such compositions particularly suitable to generate tissue separations and to prevent adhesions following surgery. The viscoelastic properties of HA make it particularly well suited for this purpose, and it is used clinically to achieve temporal pain relief by repeated intraarticular injections in arthropathies as a “joint lubricant”, as a protective agent for eye irritations and in ophthalmic surgery, as a barrier to cells in facial and other reconstructions in plastic surgery and dentistry, in reconstructive surgery of tendons, in surgical procedures in the urogenital system, and in thoracic surgery. The injectable nature of the compositions of the invention also renders them suitable for tissue augmentation in plastic surgery, where the HA matrix serves primarily as an inert biocompatible filler material (Balasz and Laurent, Hyaluronan and Its Derivatives, pp. 325-326 (1998)), e.g., for filling dermal creases or lip reconstruction.
  • HA hydrogels match several of the desired properties for a biodegradable material biocompatible with cells. The relatively simple repetitive structure of HA allows for specific modification and introduction of a large number of functional groups, for crosslinking to generate hydrogels with excellent physical properties. HA hydrogels have also successfully been used as a delivery vehicle in chondrocyte transplantation studies (Robinson et al., Calcif. Tissue Int. 46, 246-253 (1990)) and HA has proven its biocompatibility in various forms in clinical practice (for review see Laurent and Fraser, supra; Balazs and Laurent, supra).
  • The reaction mechanisms we have explored for in situ polymerization of HA derivatives are compatible with an aqueous environment and are non-toxic to cells. The aldehyde-mediated crosslinking strategies follow reactions occurring physiologically in crosslinking of fibrillar collagens and elastin. NHS-esters provide an alternative for rapid formation of stable bonds under physiological conditions, primarily by reaction with primary amines. The technology of NHS-ester-mediated protein crosslinking has been developed for materials with applications in plastic surgery that require in situ polymerization (U.S. Pat. No. 5,413,791)).
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the results of a ninhydrin test after reductive alkylation of HA and HA-aldehyde in the presence of putrescine. Reductive alkylation was carried out with an excess of putrescine in the presence of pyridine borane. HA or derivatives thereof were purified by repeated ethanol precipitation prior to detection of free amino groups on the HA chain by using the ninhydrin test (Sheng et al., Anal. Biochem. 211, 242-249 (1993)).
  • FIG. 2 shows 1H NMR of native HA (FIG. 2A) and an HA-derivative with protected aldehyde functionality (FIG. 2B) in D2O at 300 Mhz. Peaks are assigned as indicated on the structural formula.
  • FIG. 3 shows 1H NMR of HA-derivatives with amine functionality formed from putrescine (FIG. 3A), histidine (FIG. 3B), lysine (FIG. 3C), and adipic dihydrazide (FIG. 3D) in D1O at 300 Mhz. Peaks are assigned as indicated on the structural formula.
  • FIG. 4 shows digestion of crosslinked HA hydrogels with hyaluronidase. In FIG. 4A, HA-hydrogels were formed by crosslinking 12 mg/ml highly modified (˜65-70%) HA-amine (adipic dihydrazido-HA) with 15 mg/ml (SPA)2-PEG. Gels were incubated with different concentrations of bovine testicular hyaluronidase for the indicated time and the degradation of the gels was measured by the release of glucuronic acid into the supernatant using the carbazole method (Bitter and Muir, Anal Biochem. 4, 330-334 (1962)). In FIG. 4B, HA-hydrogels were formed by crosslinking 12 mg/ml optimally modified (˜20-25%) HA-amine (adipic dihydrazido-HA) with 15 mg/ml (SPA)2-PEG (⋄); 12 mg/ml highly modified (˜65-70%) adipic dihydrazido-HA with 15 mg/ml (SPA)2-PEG (Δ); 12 mg/ml optimally modified (˜20-25%) lysine methylester-HA with either 15 mg/ml (SPA)2-PEG (Λ) or 0.44 mg/ml glutaraldehyde (□), and 12 mg/ml optimally modified (˜10-15%) diaminobutyl-HA with 15 mg/ml (SPA)2-PEG (o). Gels were incubated with different concentrations of bovine testicular hyaluronidase for the indicated time and the degradation of the gels was measured as in FIG. 4A above.
  • FIG. 5 shows phase contrast images of cells cultured on different crosslinked HA hydrogels. FIG. 5A: Dedifferentiated chondrocytes cultured on a hydrogel formed from highly modified (˜65-70%) HA-amine (adipic dihydrazido-HA) crosslinked with 5 mg/ml (SPA)2-PEG aggregate as a consequence of inability to adhere to substratum. FIG. 5B: Cells cultured on a hydrogel made up by the same HA-amine crosslinked with 0.25 mg/ml glutaraldehyde show a rounded morphology and no aggregation indicating that they are able to adhere to the substratum. FIG. 5C: Cells cultured on a hydrogel formed from the HA-amine (adipic dihydrazido-HA) modified to a degree of ˜20-25% and crosslinked with 2 mg/ml (SPA)2-PEG adhere to the substratum, spread and subsequently infiltrate the hydrogel. All images show cells 24 h post seeding but morphology remains the same even after several days in culture.
  • FIG. 6 shows in vivo evaluation of HA hydrogels formed from different HA derivatives using aldehyde-mediated crosslinking. Subcutaneous implantation in rats of HA hydrogels consisting of (FIG. 6A) 12 mg/mn optimally modified (˜20-25%) HA-amine (adipic dihydrazido-HA) crosslinked with 0.25 mg/ml glutaraldehyde, (FIG. 6B) 7 mg/ml of the same HA-amine crosslinked with 7 mg/ml HA-aldehyde (periodate oxidized), (FIG. 6C) 7 mg/ml of the same HA-amine crosslinked with 7 mg/ml HA-aldehyde (deprotected amino-dimethyl acetal-HA, ˜10-15% modified), or (FIG. 6D) 7 mg/ml of the same HA-amine crosslinked with 7 mg/ml HA-aldehyde (deprotected hydrazido-dimethyl acetal-HA, ˜40-45% modified). The hydrogels also contained 1 mg/ml prefibrillized intact collagen type I, 200 μg/ml BMP-2 and 500 ng/ml IGF-1 to induce bone formation. Tissue specimens were harvested 10 days post implantation, fixed in formalin and processed for histology by paraffin embedding. Sections were stained with Haematoxylin/Eosin. mn, matrix material (note: matrix material shrinks during dehydration); s, skin (indicates orientation of implant).
  • FIG. 7 shows in vivo evaluation of HA hydrogels crosslinked with different NHS-esters. Subcutaneous implantation in rats of HA hydrogels consisting of (FIG. 7A) 12 mg/ml highly modified (˜65-70%) HA-amine (adipic dihydrazido-HA) crosslinked with 15 mg/nl (SPA)2-PEG, (FIG. 7B) 12 mg/ml optimally modified (˜20-25%) HA-amine (adipic dihydrazido-HA) crosslinked with 15 mg/ml SPA2-PEG, or (FIG. 7C) 12 mg/ml of the same optimally modified F-Lamine crosslinked with 3 mg/ml DTSSP (crosslinker concentrations are equal on a molar basis). The hydrogels also contained 1 mg/ml prefibrillized intact collagen type I, 200 μg/ml BMP-2 and 50 ng/ml TGF-β2 to induce bone formation. Tissue specimens were harvested 10 days post implantation, fixed in formalin and processed for histology by paraffin embedding. Sections were stained with Haematoxylin/Eosin. m, matrix material (note: matrix material shrinks during dehydration); s, skin (indicates orientation of implant).
  • FIG. 8 shows differential effect of growth factors incorporated into HA hydrogels on tissue transformation. Subcutaneous implantation in rats of the HA hydrogel formed from 12 mg/ml optimally modified (˜20-25%) HA-amine (adipic dihydrazido-HA) crosslinked with 15 mg/ml (SPA)1-PEG. The hydrogels also contained 1 mg/ml prefibrillized intact collagen type I, and were supplemented either with 200 μg/ml BMP-2 and 500 ng/ml IGF-1 (FIG. 8A), or 200 μg/ml BMP-2 and 50 ng/ml TGF-β2 (FIG. 8B). Tissue specimens were harvested 10 days post implantation, fixed in formalin and processed for histology by paraffin embedding. Sections were stained with Haematoxylin/Eosin.
  • BRIEF DESCRIPTION OF THE REACTION SCHEMES
  • Scheme 1 illustrates periodate oxidation of hyaluronic acid.
  • Scheme 2 illustrates coupling of amines to hyaluronic acid with EDC via an active triazole ester intermediate.
  • Scheme 3 illustrates coupling of amines to hyaluronic acid with EDC via an active N-hydroxysuccinimde ester intermediate.
  • Scheme 4 illustrates crosslinking of amnine functionalized hyaluronic acid with various bifunctional N-hydroxysuccinimde ester crosslinkers to form hydrogels. (1. (SPA)2-PEG; 2. DTSSP).
  • Scheme 5 illustrates crosslinking of amine functionalized hyaluronic acid with glutaraldehyde to form hydrogels. In addition to the conventional reaction of aldehydes with amines that results in the formation of a Schiff base, glutaraldehyde is also known to undergo polymerization by aldol condensation yielding polymers with α,β-unsaturated aldehydes at neutral or slightly alkaline pH (Richards and Knowles, J. Mol. Biol. 37, 231-233 (1968)). Subsequent, nucleophilic addition of amines at the ethylenyl double bond creates a stable crosslink.
  • Scheme 6 illustrates formation of hydrogels with aldehyde functionalized hyaluronic acid. (1. amine functionalized HA; 2. bifunctional amine)
    Figure US20070149441A1-20070628-C00002
    Figure US20070149441A1-20070628-C00003
    Figure US20070149441A1-20070628-C00004
    Figure US20070149441A1-20070628-C00005
    Figure US20070149441A1-20070628-C00006
    Figure US20070149441A1-20070628-C00007
  • DETAILED DESCRIPTION OF THE INVENTION
  • Using the methods of our invention, we generate an activated form of HA that differs minimally from native HA to conserve its unique physico-chemical properties. We also effect a minimal change affecting only a relatively small number of dissaccharide units of native HA so that we do not alter its property to serve as a cell substratum.
  • We initially attempted to generate an aldehyde derivative of HA by reduction of the carboxyl groups of the glucuronic acid moieties into aldehydes using 9-borabicyclo-3,3-nonane, a method that allows direct conversion of the carboxylic acid into the aldehyde (Cha et al., Bull. Korean Chem. Soc. 9, 48-52 (1988), Cha et al., Org. Prep. Proc. Int. 21, 451-477 (1989)):
    HA—COOH (I)→HA—CHO (II)
  • However, even though preliminary testing indicated the conversion of the carboxyl groups into aldehydes to a degree of approximately 5-10% (FIG. 1), mixtures of concentrated, viscous HA-aldehyde solutions (˜10 mg/ml) with ‘small’ polyarnines such as putrescine, lysine, polylysine, histidine, or polyhistidine did not generate stable gels in a reasonable time frame to be suitable for in situ polymerization. It is important to note that the chemical properties of HA are determined not merely by its functional groups per se but also by the accessibility of these functional groups of HA in an aqueous environment, which is related to the overall conformational structure and rheological properties of HA. HA behaves like a hydrogel in an aqueous media even in the absence of crosslinks because it forms a network stabilized by hydrogen bonds and van der Waals forces (Laurent and Fraser, supra). To increase the accessibility of functional groups, we introduced a spacer between the functional group and the HA chain.
  • Introducing a Functionalized Side Chain Onto HA
  • We subsequently developed methodology for introducing side chains into HA by carbodimide-mediated coupling of primary or secondary amines to the carboxyl group of the glucuronic acid moiety using an active ester intermediate. We have used this methodology to generate HA with different terminal functional groups for crosslinking including acetals, aldehydes, amines, and hydrazides. A wide range of functionalized amines are commercially available which allows us to introduce a wide variety of different functional groups useful for crosslinking under physiological conditions using this methodology, including maleimides that react specifically with sulfflydryls or arylazides for photocrosslinking besides the amines and aldehydes described below.
  • Direct carbodiimide-mediated coupling of amines to the carboxyl group of HA in an aqueous environment, e.g., with EDC (1-ethyl-3-[3-dimethylarninopropyl]carbodiimide), does not yield the predicted product since the O-acyl isourea that is formed as a reactive intermediate rearranges rapidly to a stable N-acyl urea (Kuo et al., supra). We have demonstrated that by “rescuing” the active O-acyl isourea by formation of a more hydrolysis resistant and non-rearrangable active ester intermediate, the coupling of primary amines to HA is possible. A wide variety of active carboxylic esters exist and could be formed for further reaction including NHS-esters, nitrophenol esters, triazole esters, sulfonic esters, etc., as long as the reagent for their preparation is soluble in H2O or in other polar solvents such as dimethylsulfoxide or dimethylformamide. HA is soluble in H2O or other aprotic polar solvents in native form and when prepared as a sodium salt or when prepared as a tetrabutylammonium salt as described in U.S. Pat. No. 4,957,744, respectively. We have formed active esters of HA with 1-hydroxybenzotriazole (HOBT) or N-hydroxysulfo-succinimide using the H2O soluble carbodiimide EDC for coupling. Nucleophilic addition to the ester formed from HOBT requires the amine to be presented in unprotonated form at acidic pH (about 5.5 to 7.0). Only a limited number of amines including hydrazines and activated amines, e.g., ethylene diamine, have pKa values in a suitable range and are consequently unprotonated and reactive with the ester-intermediate formed with HOBT (Scheme 2). Simple primary amines, e.g., putrescine, which typically have pKa values>9 do not form significant amounts of adduct under acidic coupling conditions. The N-hydroxysulfosuccinimide-derived intermediate allows for the coupling reaction to be carried out at neutral pH (about 7.0 to 8.5) and consequently yields products by reaction with simple primary amines (Scheme 3).
  • Consequently, this methodology allows for the following reactions to be carried out:
    HA—COOH (I)+H2N—R (III)→HA—CO—NH—R   (IV)
    HA—COOH (I)+R′—NH—R (V)→HA—CO—NR′—R   (VI)
    wherein R and R′ are alkyl, aryl, alkylaryl or arylalkyl side chains which may contain hetero atoms such as oxygen, nitrogen, and sulfur. The side chain may be branched or unbranched, and be saturated or may contain one or more multiple bonds. The carbon atoms of the side chain may be continuous or may be separated by one or more functional groups such as an oxygen atom, a keto group, an amino group, an oxycarbonyl group, etc. The side chain may be substituted with aryl moieties or halogen atoms, or may in whole or in part be formed by ring structures such as cyclopentyl, cyclohexyl, cycloheptyl, etc. The side chain may have a terminal functional group for crosslinking such as aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, etc. The side chain may be a bioactive peptide, e.g., containing receptor binding sites, crosslinking sites for transglutarninases, or proteolytic cleavage sites.
  • Terminal functional groups of the side chain useful for crosslinking of HA under physiological conditions may be selected from the following list:
  • 1. Aldehydes, see Examples
    H2N—R—CHO   (VII)
  • 2. Amines, see Examples
    H2N—R—NH1   (VIII)
  • 3. Arylazides, e.g., 4-(p-azidosalicylamido)butylamine
    Figure US20070149441A1-20070628-C00008
  • 4. Maleimides, e.g., 4-(N-maleimidomethyl)cyclohexane-1-carboxylhydrazide
    Figure US20070149441A1-20070628-C00009
  • 5. sulfhydryls, e.g., S-methylsulfide cysteine
    H2N—R—SH   (XI)
  • 6. Peptides, e.g., H2N-APQQEA, comprising substrate sites for enzymatic crosslinking, e.g., by transglutarninases (Parameswaran et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8472-8475 (1990); Hohenadl et al., J. Biol. Chem. 270, 23415-23420 (1995)).
  • The carbodiimides useful in this reaction may be represented by the following formula:
    R—N═C═N—R′  (XII)
    wherein R and R′ comprise side chains of variable structure as described above in detail. Carbodiimides which are soluble in an aqueous media are preferred.
  • The active ester may be of the following class and be formed by carbodiimide-mediated coupling of a compound for preparation of these active esters known to a person in the art:
  • 1. Triazole Esters, e.g. 1-hydroxybenzotriazole
    Figure US20070149441A1-20070628-C00010
  • 2. NHS-Esters, e.g. N-hydroxysulfosuccinimide
    Figure US20070149441A1-20070628-C00011
  • 3. nitrophenol esters, e.g. p-nitrophenol
    Figure US20070149441A1-20070628-C00012

    Preparation of HA-aldehyde Derivatives
  • A side chain containing a protected aldehyde in the form of an acetal was prepared as follows. N-(2,2-dimethoxyethyl)-4-(methoxycarbonyl)butanamide was obtained from aminoacet-aldehyde dimethyl acetal and mono-methyl succinate using EDC coupling. An amino group for the coupling to HA was subsequently introduced by reacting the product with hydrazine, yielding the desired side chain with the protected aldehyde, N-(2,2-dimethoxyethyl)-4-(hydrazido)butanamide. The side chain was coupled to HA using HOBT and EDC (Scheme 2). An acetal side chain with a simple primary amine, 1-aminoethyl-dimethylacetal, was conjugated to HA using N-hydroxysuccinimide and EDC (Scheme 3). The HA-derivatives were purified by ethanol precipitation. The nature of the HA-derivatives was confirmed by 1H NMR (FIG. 2). The HA-acetal derivatives are easily activated to the reactive aldehydes by mild acid treatment. Other HA-aldehyde derivatives with variations in the length of the side chain have been prepared in a similar manner. See Examples 1-3.
  • Preparation of HA-amine Derivatives
  • Diaminoethane, lysine methyl ester, histidine, and adipic, succinic or suberic dihydrazide was coupled to HA using HOBT and EDC (up to 5-fold excess depending on the desired degree of modification) and adjusting the pH to ˜6.5 by repeated addition of 0.1M HCl during the reaction (Scheme 2). HA-derivatives were also prepared in a similar manner using N-hydroxysulfosuccinimide and primary amines containing unconjugated amino groups with a higher pKa (>9) such as 1,4-diaminobutane or 1,6 diaminohexane (Scheme 3). The HA derivatives were purified by repeated ethanol precipitation and by extensive dialysis, and the nature of the HA derivatives was confirmed by 1H NMR (FIG. 3). The degree of modification was calculated from the NMR data and found to be as high as 70%. Reaction conditions were subsequently adjusted such that a degree of modification of approximately 20% was achieved. Limiting the amount of carbodiimide proved to be most successful in controlling the degree of modification. A degree of modification of 10-25% yielded efficient crosslinking but also a molecule that would still be recognized by glycosidases and by HA receptors as HA and thus allow for recognition and processing of the material by cells (see below). Similar HA derivatives were synthesized using succinic, adipic or suberic dihydrazide or diaminoethane, -butane, or -hexane to study the effect of the length of the spacer separating the introduced functional group from the HA-chain on the subsequent crosslinking. See Examples 4-8.
  • Crosslinked HA Hydrogels
  • The functionalized HA molecules can be crosslinked by reacting HA derivatives with different functionalities or using homo- or heterobifunctional crosslinkers which are available in large variety. The following basic reaction schemes are suitable for crosslinking of the described forms of modified HA (see Examples 9-12):
  • 1. Aldehyde-Mediated Crosslinking
    R1—CHO+H2N—R2→R1—CH═N—R2
  • 2. Active Ester-Mediated Crosslinking
    Figure US20070149441A1-20070628-C00013
  • 3. Maleimide-Mediated Crosslinking
    Figure US20070149441A1-20070628-C00014
  • 4. Photo-Crosslinking
    Figure US20070149441A1-20070628-C00015
  • 5. Enzymatic Crosslinking (transglutaminase)
    R1—(CH)2—CONH2+H2N—R2→R1—(CH)2—CO—NH—R2
  • Crosslinking of the HA-amine derivatives (Mr˜106) with bifunctional active esters, e.g. polyethyleneglycol-bis-succinimnidyl-propionate [(SPA)2-PEG] and reducible 3,3′-dithiobis(sulfo-succinimidyl-propionate) (DTSSP) (Scheme 4), or bifunctional aldehydes, e.g. glutaraldehyde (Scheme 5), generated excellent hydrogels. Stable gels could be formed by crosslinking 5 to 25 mg/ml HA derivative with >0.05 mM aldehyde or >0.2 mM active ester (numbers are reflecting functional group concentrations). Optimal gels were generated by crosslinking 10-15mg/ml HA derivative, modified to a degree of about 10-25%, with about 0.2 mM aldehyde or 0.6 mM active ester. Similarly, crosslinking of the HA-aldehyde derivatives (Mr˜106) (optimally about 10-15 mg/ml) with bifunctional amines (optimally about 0.2 mM) yielded excellent gels (Scheme 6). Conjugated amines such as dihydrazines or benzylamines are required for in situ polymerization of HA in this case to resonance stabilize the instable Schiff base product formed by reaction of an aldehyde with a primary amine (i.e. hydrazines yield a more stable hydrazone linkage). Hydrogels were also formed from an equimolar mixture of HA-aldehyde derivatives and the different HA-amine derivatives (Scheme 6). Optimal gels were formed with ˜15 mg/ml of the HA derivatives. At the optimal concentrations of HA and crosslinker, gelation occurred typically in about 30 sec. to 5 min. which is suitable for in situ polymerization. The crosslinked HA hydrogels were sensitive to glycosidases, i.e. testicular hyaluronidase, indicating that they are biodegradable (FIG. 4).
  • A number of different tests including cell culture assays and animal experiments served to assess biocompatibilty of the formulated biomaterials. Embedding of chondrocytes into the polymerizing HA hydrogels showed that neither aldehyde nor NHS-ester-mediated crosslinking was toxic to cells at the concentrations employed. Seeding of cells on top of prepolymerized HA hydrogels showed a wide variety of cellular behaviours depending on the nature of the crosslinker and crosslinking density (FIG. 5). Highly crosslinked HA hydrogels were impenetrable to cells (FIGS. 5, A and B), while optimally crosslinked gels were infiltrated (FIG. 5C). Supplementation of the HA hydrogels with cell adhesion molecules such as fibronectin (in the range of 0.1 to 1 mg/ml) did induce adhesion and spreading of cells on the materials independent of the nature of the crosslinker and the crosslinking density, but did not change the results with regard to cell infiltration, demonstrating that the lack of infiltration is due to the high crosslinking density and not the absence of cell-matrix interactions. See below and FIG. 7.
  • Subcutaneous implantation of biomaterials in rats is the established model for evaluation of biocompatibility of biomaterials (Laurencin et al., J. Biomed. Mat. Res. 24, 1463-1481 (1990)) and for induction of ectopic bone formation by members of the TGF-β gene family, and bone morphogenetic proteins (BMP) in particular (Wang et al., Proc. Natl. Acad. Sci. U.S.A. 87, 2220-2224 (1990); Sampath et al., J. Biol. Chem. 267, 20352-20362 (1992)). Taking into consideration the cell culture results, we have formulated a number of HA hydrogels for in vivo biocompatibility testing in this model. Implantation of prepolymerized HA hydrogel discs loaded with recombinant BMP-2 and IGF-1 or TGF-β2 subcutaneously in rats showed a mild fibrosis with a varying degree of cartilage and bone formation depending on the nature of the HA biomaterial (FIGS. 6 and 7). The growth factors were mixed with the HA derivatives prior to gelling and the induction of bone formation suggests that neither reaction mechanism used for HA crosslinking (aldehyde or active ester-mediated reactions) significantly affected the biological activity of the growth factors. Little inflammation was observed with active ester crosslinked HA-amine derivatives (FIG. 7) or with HA-amine derivatives crosslinked with various HA-aldehyde derivatives (FIGS. 6B-6D) while a stimulation of foreign body giant cells was seen when the same HA-amine derivatives were crosslinked with glutaraldehyde (FIG. 6A). The degree of modification of HA strongly affected the resorption and transformation rate of the biomaterials (FIGS. 7A, 7B). Nevertheless, limited bone formation was seen even with a biomaterial formed from a highly modified (65-70%) HA-amine derivative (FIG. 7A). The absence of bone formation with a smaller bifunctional NHS-ester crosslinker indicates that the size of the generated crossbridge is crucial for resorption and cellular infiltration (FIG. 7C). This is probably due to the difference in pore size of the material formed with crosslinkers of different sizes. The infiltration and transformation rate was similar with BMP-2/IGF-1 and BMP-2/TGF-β2 loaded biomaterials, indicating that the resorption rate is a material property. However, at ten days post-implantation, the newly formed tissue was largely cartilage in the first group and largely bone in the second group (FIG. 8), exemplifying the angiogenic effect of TGF-β2 (Yang and Moses, J. Cell. Biol., 111, 731-741 (1990)). This demonstrates that the biological activity of the HA material can be modulated by inclusion of different bioactive factors. The lack of significant adverse effects and the demonstration of the desired biological activity of these novel HA biomaterials in vivo demonstrates their usefulness as a delivery vehicle for cells and growth factors in the field of tissue regeneration.
  • There are several approaches to the production of HA, including extraction from tissue and biosynthesis. Extraction from tissue typically uses fresh or frozen cocks' combs (U.S. Pat. No. 5,336,767), although other tissues including the synovial fluid of joints (Kvam et al., Anal. Biochem. 211, 44-49 (1993)), human umbilical cord tissue, bovine vitreous humor, and bovine tracheae, have been used. It is also possible to prepare HA by microbiological methods, such as by cultivating a microorganism belonging to the genus Streptococcus which is anhemolytic and capable of producing HA in a culture medium (U.S. Pat. Nos. 4,897,349; 4,801,539; 4,780,414; 4,517,295; 5,316,926). The HA raw material for preparing the compositions of the invention preferably consists of high molecular weight HA, more preferably of molecular weight greater than 0.5 million daltons, and more preferably of molecular weight greater than one million daltons. The HA raw material for the compositions of examples of this invention described herein was obtained from Genzyme Corp. (Cambridge, Mass.), and had a molecular weight greater than one million daltons. The size of the HA was unchanged after derivatization.
  • The compositions of the invention have many therapeutic uses. The fact that the compositions may be cured in a surgically practical time frame of one to five minutes in situ with concurrent crosslinking to the tissue surfaces allows for employment as a tissue glue. Many situations in various surgical applications require such adhesives. For example, the compositions of the invention may be used to stem hemorrhage in general surgery, reconstruct nerves and vessels in reconstructive, neuro- and plastic surgery, and to anchor skin, vascular, or cartilage transplants or grafts in orthopedic, vascular, and plastic surgery. Those of skill in the art may choose and design particular embodiments of the invention which are particularly suitable for a desired application, by adjusting several factors, including: (1) the degree of functionalization of HA, which affects the crosslinking density of the material and interaction with cellular proteins, including receptors and glycosidases; (2) the concentration of the crosslinker, which affects the crosslinking density of the material; (3) the size of the generated cross-bridge, which affects the pore size of the material; (4) the nature of the crosslinking mechanism, which determines polymerization time and the specificity of the reaction; and (5) the nature of the cross-bridge, which provides biological cues. See FIGS. 4, 5, and 7 for data concerning HA hydrogels with different crosslinking densities and pore sizes. Generally, active ester- or photo-crosslinking are preferred to form materials for applications requiring fast gelation and strong bonding with tissue surfaces, such as tissue glues. Materials with anti-adhesive properties, which are useful to form tissue separations or for tissue augmentation, are formed from highly modified HA derivatives with low molecular weight crosslinkers, which generates a dense material with very small pores, thereby minimizing cell adhesion and infiltration. Conversely, biodegradable scaffolds for tissue repair are formed from HA with a limited degree of derivativization and high molecular weight crosslinkers, which generate a porous, biodegradable material. The crossbridge may even contain biological cues, such as peptide sequences, which facilitate material degradation by, for example, proteolysis or cellular infiltration (e.g., the RGD sequence).
  • Compositions of this invention were designed to serve as a vehicle for the delivery of cells or bioactive molecules such as growth factors to stimulate focal repair. The crosslinked HA derivatives are porous hydrogels in which biologically or therapeutically active compounds (e.g., growth factors, cytokines, drugs, and the like) can be physically or chemically incorporated. These compounds will then be subject to sustained release by chemical, enzymatic, and physical erosion of the hydrogel and/or the covalent linkage between the HA chain and biologically active compound over a period of time. Local delivery of growth factors with such a scaffold facilitates wound healing and tissue regeneration in many situations. For example, the compositions of the invention may be used not only to promote bone formation and stimulate cartilage repair in orthopedic procedures, as described more fully below, but also to treat pathological wound conditions such as chronic ulcers. They may also serve as a scaffold to generate artificial tissues, e.g., cartilage (Hauselmann et al., Am. J. Physiol. 271, C742-752 (1996)), through proliferation of autologous cells in culture. Similar procedures for generation of equivalents of other tissues or organs, including skin, liver, and others, in culture may be developed in the future and may be used in combination with the compositions of the invention.
  • Highly crosslinked materials have an anti-adhesive property with respect to cells, and such compositions may be used to generate tissue separations and to prevent adhesions following surgery. See FIGS. 5A and 7C, showing highly modified HA-amine, i.e., adipic dihyrazido HA, preferably crosslinked with low molecular weight bifunctional NHS-ester. The viscoelastic properties of HA make it particularly well suited for this purpose, and it is used clinically to achieve temporal pain relief by repeated intraarticular injections in arthropathies as a “joint lubricant”, and as a protective agent for eye irritations and in ophthalmic surgery. The technique of tissue separation is used in facial reconstruction in plastic surgery and dentistry. Prevention of the formation of adhesions is particularly relevant in reconstructive surgery of tendons, in surgical procedures in the urogenital system, and in thoracic surgery. Many different HA-based materials are already in clinical use in these areas. (See products manufactured by Anika Therapeutics, Inc. (Woburn, Mass.), Biomatrix, Inc. (Ridgefield, N.J.), Genzyme Corp. (Cambridge, Mass.), and Fidia, S.p.A. (Abano Terme, Italy)). Those of skill in the art may choose and design particular embodiments of the invention which are particularly suitable for a desired application by selecting distinct features as outlined above.
  • The injectable nature of the compositions of the invention also renders them suitable for tissue augmentation in plastic surgery, where the HA matrix serves primarily as a biocompatible filler material, e.g., for filling dermal creases or lip reconstruction. Again, those of skill in the art may choose and design particular embodiments of the invention which are particularly suitable for a desired application, as outlined above.
  • The half-life of pharmacological compounds, both synthetic and biological, has been shown to be drastically increased when delivered in a form conjugated to HA (Larsen and Balazs, Adv. Drug Delivery Rev. 7, 279-293 (1991), Drobnik, J., Drug Delivery Rev. 7, 295-308 (1991)). The functionalized forms of HA provided by this invention allow for easy substitution with pharmacologically active agents, such as anti-inflammatories, analgesics, steroids, cardiovascular agents, anti-tumor agents, immunosuppressants, sedatives, anti-bacterial, anti-fungal, and anti-viral agents, etc., and may be used for sustained drug release over time, either locally in hydrogel form or systemically in free form.
  • In orthopedic surgery, the functionalized forms of HA of this invention have applications as a tissue glue or bioactive matrix material in the treatment of chondral and osteochondral fractures, osteochondritis dissecans, meniscal tears, as well as ruptured ligaments, tendons, or myotendineous junctions. The HA materials of this invention may serve to facilitate anchorage of chondral or osteochondral transplants or grafts, or other biological or artificial implant materials, or to stimulate new bone or cartilage formation by serving as a scaffold for cells or as a delivery vehicle for growth factors. One general approach to promote articular cartilage repair based on the compositions of the invention comprises using: (1) in situ polymerized HA hydrogel as a matrix to fill the defect which is to be repaired and to provide a scaffold for repair cells, (2) an optional chemotactic agent to attract repair cells to the matrix and defect site, or alternatively, autologous chondrocytes or mesenchymal stem cells, (3) an optional factor to promote cellular proliferation of repair cells in the matrix and defect site; (4) sustained release of a transforming factor by the HA hydrogel over time to promote differentiation of the repair cells into chondrocytes which produce new cartilage; and (5) an optional anti-angiogenic factor to prevent vascularization and endochondral ossification of the newly formed cartilage. Examples of suitable factors are known to those skilled in the art, and may be found in, e.g., U.S. Pat. No. 5,368,858.
  • Delivery of growth factors in active form may require supplementation of the HA hydrogels with additional ingredients, such as growth factor binding molecules like heparin and collagen. For example, for cartilage repair, crosslinked hyaluronic acid hydrogels that are rapidly infiltrated by cells such as those formed from an HA-amine derivative crosslinked with a polyvalent high molecular weight NHS-ester crosslinker, e.g., (SPAs-PEG, are selected which are resorbed and replaced by repair tissue within about 2 to 3 weeks. In some cases, cells and/or growth factors may be mixed in prior to gelling.
  • The following are illustrative examples, which are not intended to limit the scope of the present invention.
  • EXAMPLES Example 1
  • Preparation of N-(2,2-dimethoxyethyl)-4-(methoxycarbonyl)butanamide (1) - EDC (4.98 g, 0.026 mol) was added to a mixture of aminoacetaldehyde dimethyl acetal (2.18 ml, 20 mmol) and methyl monoester of succinic acid (2.64 g, 20 mmol) in 75 ml of dichloromethane, and the reaction mixture stirred for 24 h at room temperature. The solution was extracted successively with 50 ml each of ice cold solutions of 0.75M sulfuric acid, 1M NaCl, saturated sodium bicarbonate, and 1M NaCl. The organic phase was collected and dried with sodium sulfate. The solvent was evaporated under reduced pressure yielding a syrup, which showed a single spot on charring upon TLC in solvent A (Rf 0.75) and solvent B (Rf 0.24). The apparent yield of 1 was 65%.
  • 1H NMR in CDCl3 δ 5.70 (bs, 1H, NH), 4.34 [t, 1H, CH—(OCH3), 3.67 (s, 3H, COOCH3), 3.43-3.35 (s and t, 8H, CH3OC and CHCH2NH), 2.38-2.26 (m, 4H, CH2CO).
  • Formation of Acyl-hydrazide (2) from 1-Anhydrous hydrazine (248 μl, 7.9 mmol) was added to a solution of 1 (1.73 g, 7.9 mmol) in 5 ml of anhydrous methanol. The mixture was stirred at room temperature overnight and the solvent subsequently evaporated under reduced pressure yielding a solid residue. The residue was dissolved in H2O (6 ml) and extracted three times with an equal volume of dichloromethane. The aqueous solution was evaporated to dryness under reduced pressure and then further dried overnight in vacuo. The crystaline solid (1.04 g, 82% yield) was homogeneous on TLC in solvent A (Rf 0.10) when visualized by charring. The 1H NMR spectrum indicated the loss of the ester methoxy group when compared to 1.
  • Preparation of Hydrazido-dimethyl acetal-HA (formula XIX) -Sodium hyaluronate (100 mg, 0.25 mmol) and N-(2,2-dimethoxyethyl)-4-(hydrazido)butanamide (2) (1.646 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2. See FIG. 2B for NMR data of the product.
    Figure US20070149441A1-20070628-C00016
  • Example 2
  • Preparation of Aminoacetaldehyde-dimethyl acetal-HA (formula XX)-Sodium hyaluronate (100 mg, 0.25 mmol) and 2,2-dimethoxyethylarnine (0.788 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 7.5 and NHS.SO3Na (268 mg, 1.25 mmol) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2.
    Figure US20070149441A1-20070628-C00017
  • Example 3
  • Deprotection of HA-acetals to form HA-aldehydes—The acetal modified HA(formula XII) was dissolved in H2O to a concentration of 5-10 mg/ml and 1M HCl was added to give a final concentration of 0.025M. The solution was then allowed to stand at room temperature for 0.5 to 1.0 h. The solution was neutralized by the addition of 1M NaOH, yielding the deprotected HA-aldehyde (formula XXII).
    HA—CO—R—CH(OCH3)2 (XXI)→HA—CO—R—CHO   (XXII)
  • Example 4
  • Preparation of Diaminoethane-HA (formula XXIII)—Sodium hyaluronate (100 mg, 0.25 mmol) and 1,2-diaminoethane HCl (0.998 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2.
    Figure US20070149441A1-20070628-C00018
  • Example 5
  • Preparation of L-Lysine methyl ester-HA (formula XXIV)—Sodium hyaluronate (100 mg, 0.25 mmol) and L-lysine methyl ester dihydrochloride (1.748 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2. See FIG. 3C for NMR data of the product.
    Figure US20070149441A1-20070628-C00019
  • Example 6
  • Preparation of L-Histidine methyl ester HA (formula XXV)—Sodium hyaluronate (100 mg, 0.25 mmol) and L-histidine methyl ester dihydrochloride (1.815 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT(169 mg, 1.25 mmol) predissolved in a 1:1 mixture of H2O and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCl added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2. See FIG. 3B for NMR data of the product.
    Figure US20070149441A1-20070628-C00020
  • Example 7
  • Preparation of Hydrazido-HA (formula XXVI)—Sodium hyaluronate (100 mg, 0.25 mmol) and dihydrazide i.e. adipic dihydrazide (1.31 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 6.5 and HOBT (169 mg, 1.25 mmol) predissolved in a 1:1 mixture of water and DMSO (1 ml) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1 M NaOH and NaCl added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2. See FIG. 3D for NMR data of the product.
    Figure US20070149441A1-20070628-C00021
  • Example 8
  • Preparation of Diaminoalkyl-HA (formula XXVII)—Sodium hyaluronate (100 mg, 0.25 mmol) and a diaminoalkane, i.e. 1,2-diaminobutane HCl (1.208 g, 7.5 mmol) was dissolved in H2O (40 ml, 2.5 mg/ml HA). The pH was adjusted to 7.5 and NHS.S03Na (268 mg, 1.25 mmol) and EDC (240 mg, 1.25 mmol) was added and the reaction mixture was stirred overnight. The pH was subsequently adjusted to 7.0 with 1M NaOH and NaCG added to produce a 5% w/v solution. HA was precipitated by addition of three volume equivalents of ethanol. The precipitate was redissolved in H2O at a concentration of approximately 5 mg/ml and the precipitation repeated twice. The purified product was freeze dried and kept at 4° C. under N2. See FIG. 3A for NMR data of the product.
    Figure US20070149441A1-20070628-C00022
  • Example 9
  • Formation of crosslinked HA hydrogels—The general procedure for forming crosslinked HA hydrogels is as follows: Modified HA is dissolved by agitation in H2O or phosphate buffered saline (pH 7.4-8.5) at a concentration of 5-25 mg/ml. The degree of modification of the HA derivative is derived from the integration of the 1H NMR peaks. After complete dissolution, the HA derivative solution is transferred to a 1 ml syringe. When reacting the HA derivatives with low molecular weight crosslinkers, a slight excess of the compound (about 1.1 molar equivalent of functional groups) is dissolved in a second 1 ml syringe in 1/10 of the HA derivative volume immediately prior to use. The syringes are connected while paying special attention to excluded air, the contents are rapidly mixed, typically with 20 passages, and then extruded. When reacting HA derivative molecules with different functionalities, 0.5-1.0 equivalent of HA-aldehyde is mixed with 1 equivalent of HA-hydrazine, depending on the degree of modification of the HA derivatives. At room temperature, gelation occurs within about 30 seconds to several minutes, depending on the formulation, and the gel properties do not significantly change after approximately 5 minutes.
  • Example 10
  • Digestion of crosslinked HA hydrogels with hyaluronidase—The general procedure for digestion of crosslinked HA hydrogels is as follows: HA hydrogels are formed in 1 ml syringes by crosslinking 12 mg/ml HA-amnine in phosphate buffered saline with various crosslinkers as indicated in FIG. 4. Gelling is allowed to occur for 1 hour at 37° C. for the reaction to be complete, after which identical ˜100 μl cylindrical gels are formed by cutting the syringes with a razor blade. The gels are incubated with different concentrations of bovine testicular hyaluronidase (Sigma) 50-5000 U/mL in 400 μl of 30 mM citric acid, 150 mM Na2HPO4, pH 6.3, 150 mM NaCl for the indicated time 0-48 hours. Degradation of the gels is determined from the release of glucuronic acid into the supernatant as measured using the carbazole method (Bitter and Muir, supra). See FIG. 4.
  • Example 11
  • Crosslinked HA hydrogels as a matrix for cell culture—Chondrocytes were isolated from bovine nose cartilage according to established procedures (Hauselmann et al., Matrix 12, 116-129 (1992; Kuttner et al., J. Cell Biol. 93, 743-750 (1982)), cultured in Ham's F12 medium containing 5% fetal bovine serum and antibiotics, and dedifferentiated by monolayer culture on plastic. For cytotoxicity studies, cells (2.5×105) were embedded into the HA hydrogels by gently mixing the trypsinized cells ( about 50 to 100 μl) with the polymerizing HA and crosslinker mixture (approximately 400 μl gel volume) prior to complete setting. Agarose embedded cells served as a control. After adaptation to the culture conditions (24 h), cell proliferation and metabolic activity was assessed by pulse labeling with [3H]thynfidine and [35S]methionine. For cell infiltration studies, HA hydrogels were polymerized in 24-well plates (˜15mm diameter and 3mm height) for 1 h at room temperature, and extensively rinsed with phosphate buffered saline. Cell adhesion molecules or chemotactic factors, e.g. IGF-1, were added to the HA solution prior to crosslinking when desired. After 24 h, cells (2.5×105) were seeded on top of the HA-hydrogels and cultured as above. At different time points post seeding, gels were fixed in phosphate buffered 4% paraformaldehyde and processed for paraffin embedding. Cell infiltration was assessed by staining sections with Haematoxylin/Eosin. See FIG. 5.
  • Example 12
  • Subcutaneous implantation of HA hydrogels in rats—Rats (2-3 per test material) were anaesthetized with ketamine/xylazine, the ventral thorax and abdomen shaved, and prepared aseptically. A small vertical incision was made on either side of the xiphoid cartilage of the sternum and the skin undermined with a blunt instrument to separate the skin from the underlying tissue. HA hydrogels were polymerized in 3 ml syringes as described. For induction of chondro-osseous differentiation, 1 mg/ml prefibrillized intact collagen type I (Organogenesis, Canton, Mass.), 200 μg/ml recombinant BMP-2 (Genetics Institute, Cambridge, Mass.), and 500 ng/ml IGF-1 (Celtrix Pharmaceuticals, Santa Clara, Calif.) or 50 ng/ml TGF-β2 (Celtrix Pharmaceuticals, Santa Clara, Calif.) were mixed with the HA solution prior to crosslinking. Collagen fibrils were prepared by slow polymerization (from dilute solutions of 2-3 mg/ml) of acid-solubilized couagen in phosphate buffered saline and harvested by centrifugation following standard protocols (McPherson et al., Collagen Rel. Res. 5, 119-135 (1985)). Gelling of the HA hydrogels was allowed to occur for 24 h at room temperature for the reaction to be complete, after which identical ˜3mm thick cylindrical gels were prepared by cutting the syringes with a razor blade. HA hydrogel discs were then placed in each pocket and the skin incisions closed with sutures. Ten days post operatively, the rats were euthanized and the appearance of the implant sites, i.e. degree of inflammation, grossly examined and tissue specimens harvested and processed for histology by fixation in phosphate buffered formalin and paraffin embedding. Sections were stained with Haematoxylin/Eosin and with Safranin-O/fast green, and cell infiltration and transformation (cartilage and bone formation) induced by the biomaterial as well as signs of fibrosis and inflammation in the surrounding tissue evaluated. See FIGS. 6-8.

Claims (33)

1. A composition comprising derivatives of hyaluronic acid (ha) comprising disaccharide: subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00023
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from hydrogen, peptide, aldehyde, amine, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl,
wherein said terminal functional groups of each of said R′ and R″ side chains may be bound directly to each other, with the proviso that when one of R′ or R″ is hydrogen, halogen or univalent metal ion, then R′ and R″ may not be bound directly to each other, and
wherein said derivatives of hyaluronic acid are covalently crosslinked via one of said terminal functional groups.
2. The composition of claim 1, wherein at least one of said terminal functional groups is selected from peptide, aldehyde, amine, hydrazide, maleimide, sulfhydryl and active ester, whereby said composition is amenable to crosslinking.
3. The composition of claim 1, wherein the molecular weight of said composition is at least 100,000 daltons.
4. The composition of claim 1, wherein the molecular weight of said composition is at most 100,000 daltons.
5. The composition of claim 1, wherein the molecular weight of said composition is at least 1,000,000 daltons.
6. The composition of claim 1, wherein said composition is water soluble.
7. A hydrogel of crosslinked HA derivatives, wherein said HA derivatives are compositions according to claim 1.
8. The hydrogel of crosslinked HA derivatives of claim 7, wherein said hydrogel is biodegradable.
9. A tissue adhesive comprising a hydrogel of claim 7, wherein the side chain is selected from activated ester, aldehyde and maleimide.
10. A tissue adhesive comprising a hydrogel of claim 7, wherein the crosslinked HA derivatives are formed using a cross-linker selected from polyvalent active ester, aldehyde and maleimide.
11. A tissue adhesive comprising a hydrogel of claim 7, wherein the crosslinked hydrogel is formed in the presence of at least one member selected from growth factors, cytokines, drugs, and bioactive peptides.
12. The tissue adhesive of claim 11, wherein the crosslinked hydrogel is formed in the presence of a growth factor and wherein the growth factor is TGF-beta or BMP-2.
13. A matrix for cell cultures comprising the hydrogel of claim 7, wherein the crosslinked HA-derivatives are formed using a cross-linker selected from polyvalent active ester, aldehyde, amine, arylazide, maleimide, and sulfhydryl.
14. A matrix for cell cultures comprising the hydrogel of claim 7, wherein the crosslinked hydrogel is formed in the presence of at least one member selected from growth factors, cytokines, drugs, and bioactive peptides.
15. The matrix of claim 14, wherein the crosslinked hydrogel is formed in the presence of a growth factor and wherein the growth factor is TGF-beta or BMP-2.
16. A matrix for a scaffold comprising the hydrogel of claim 7, wherein the crosslinked HA-derivatives are formed using a cross-linker selected from polyvalent active ester, aldehyde, amine, maleimide and sulfhydryl.
17. A matrix for a scaffold comprising the hydrogel of claim 7, wherein the crosslinked hydrogel is formed in the presence of at least one member selected from growth factors, cytokines, drugs, and bioactive peptides.
18. The matrix of claim 17, wherein the crosslinked hydrogel is formed in the presence of a growth factor and wherein the growth factor is TGF-beta or BMP-2.
19. The matrix of claim 17, wherein the matrix further comprises cells.
20. A method of forming a crosslinked biodegradable material under physiological conditions from a composition comprising derivatives of hyaluronic acid comprising disaccharide subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00024
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from the group consisting of hydrogen, peptide, aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl; and
wherein said derivatives of hyaluronic acid are modified to an extent of more than 10%,
21. The method of claim 20, wherein the material is formed in situ.
22. A method of regenerating tissue or causing tissue adhesion, comprising contacting a tissue with a composition comprising derivatives of hyaluronic acid comprising disaccharide subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00025
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from the group consisting of hydrogen, peptide, aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl; and
wherein said derivatives of hyaluronic acid are modified to an extent of more than 10%.
23. The method of claim 22, wherein the method comprising one or more of repairing cartilage, stemming hemorraging, reconstructing nerves and/or vessels, and anchoring skin, vascular or cartilage transplants or grafts.
24. A method of delivering cells or bioactive materials, comprising delivering the cells or bioactive materials in a composition comprising derivatives of hyaluronic acid comprising disaccharide subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00026
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from the group consisting of hydrogen, peptide, aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl; and
wherein said derivatives of hyaluronic acid are modified to an extent of more than 10%.
25. The method of claim 24, wherein the bioactive material is a growth factor.
26. The method of claim 24, wherein the cells or bioactive material are delivered to treat a pathological wound condition.
27. A method of generating tissue separation or preventing tissue adhesions, comprising contacting tissue with a composition comprising derivatives of hyaluronic acid comprising disaccharide subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00027
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from the group consisting of hydrogen, peptide, aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl; and
wherein said derivatives of hyaluronic acid are modified to an extent of more than 10%,.
28. The method of claim 27, wherein the tissue separation or prevention of tissue adhesions is effective for joint lubrication, prevention of eye irritation or serving as a barrier to cells.
29. A method of augmenting tissue, comprising contacting tissue with a composition comprising derivatives of hyaluronic acid comprising disaccharide subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00028
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from the group consisting of hydrogen, peptide, aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl; and
wherein said derivatives of hyaluronic acid are modified to an extent of more than 10%.
30. The method of claim 29, wherein the tissue augmentation is effective for filling dermal creases or lip reconstruction.
31. A method of sustaining drug release, comprising conjugating one or more pharmacological compounds to a composition comprising derivatives of hyaluronic acid comprising disaccharide subunits, wherein at least one of said disaccharide subunits is a substituted disaccharide subunit having a substitution at a carboxyl group, such that the substituted disaccharide subunit is of the formula:
Figure US20070149441A1-20070628-C00029
wherein each of R′ and R″ is a side chain comprising one or more functional groups selected from the group consisting of hydrogen; bioactive peptide; alkyl; aryl; alkylaryl; arylalkyl; substituted alkylaryl containing an atom or atoms of oxygen, nitrogen, sulfur, or phosphorous; substituted arylalkyl containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen, or metal ion; and substituted heterocycle containing an atom or atoms of oxygen, nitrogen, sulfur, phosphorous, halogen or metal ion;
wherein said functional groups within or among each of said R′ or R″ side chains are either bound directly to each other or are separated by a member selected from the group consisting of ether, keto, amino, oxycarbonyl, sulfate, sulfoxide, carboxamide, alkyne and alkene; and
wherein each of said R′ and R″ side chains terminates with a terminal functional group selected from the group consisting of hydrogen, peptide, aldehyde, amine, arylazide, hydrazide, maleimide, sulfhydryl, active ester, ester, carboxylate, imidoester, halogen and hydroxyl; and
wherein said derivatives of hyaluronic acid are modified to an extent of more than 10%,
wherein the one or more pharmacological compounds are conjugated to the derivatives of hyaluronic acid.
32. The method of claim 31, wherein the composition is in a free form.
33. The method of claim 31, wherein the pharmacological compound is selected from anti-inflammatories, analgesics, steroids, cardiovascular agents, anti-tumor agents, immunosuppressants, sedatives, anti-bacterials, anti-fungals and anti-virals.
US11/706,922 1998-09-18 2007-02-13 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same Abandoned US20070149441A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/706,922 US20070149441A1 (en) 1998-09-18 2007-02-13 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/156,829 US6630457B1 (en) 1998-09-18 1998-09-18 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US10/680,000 US7196180B2 (en) 1998-09-18 2003-10-06 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US11/706,922 US20070149441A1 (en) 1998-09-18 2007-02-13 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/680,000 Continuation US7196180B2 (en) 1998-09-18 2003-10-06 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same

Publications (1)

Publication Number Publication Date
US20070149441A1 true US20070149441A1 (en) 2007-06-28

Family

ID=22561268

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/156,829 Expired - Fee Related US6630457B1 (en) 1998-09-18 1998-09-18 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US10/680,000 Expired - Fee Related US7196180B2 (en) 1998-09-18 2003-10-06 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US11/706,922 Abandoned US20070149441A1 (en) 1998-09-18 2007-02-13 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/156,829 Expired - Fee Related US6630457B1 (en) 1998-09-18 1998-09-18 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US10/680,000 Expired - Fee Related US7196180B2 (en) 1998-09-18 2003-10-06 Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same

Country Status (8)

Country Link
US (3) US6630457B1 (en)
EP (2) EP1757314A1 (en)
AT (1) ATE284229T1 (en)
AU (1) AU6192299A (en)
CA (1) CA2344215A1 (en)
DE (1) DE69922522T2 (en)
IL (2) IL142068A0 (en)
WO (1) WO2000016818A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293648A1 (en) * 2006-04-28 2007-12-20 Heather Sheardown Hyaluronic acid-retaining polymers
US20100272761A1 (en) * 2009-04-24 2010-10-28 Seoul National University of Technology Center for Industrial Collaboration Synthesis of lipoamide-grafted high molecular compound and method therefor
US20100279952A1 (en) * 2007-12-21 2010-11-04 Ninus Caram-Lelham Cross-linked hydrogel containing an active substance
US20110008444A1 (en) * 2008-02-29 2011-01-13 Ipr-Systems Sweden Ab Composition for the formation of gels
US20120276069A1 (en) * 2009-11-11 2012-11-01 Hermanus Bernardus Johannes Karperien Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
US20120301441A1 (en) * 2009-11-11 2012-11-29 Hermanus Bernardus Johannes Karperien Dextran-hyaluronic acid based hydrogels
WO2013036072A1 (en) * 2011-09-08 2013-03-14 신풍제약 주식회사 Injectable therapeutic agent for arthritis
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
CZ303879B6 (en) * 2012-02-28 2013-06-05 Contipro Biotech S.R.O. Derivatives based on hyaluronic acid capable of forming hydrogels, process of their preparation, hydrogels based on these derivatives, process of their preparation and use
US8497023B2 (en) 2008-08-05 2013-07-30 Biomimedica, Inc. Polyurethane-grafted hydrogels
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US8679190B2 (en) 2004-10-05 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Hydrogel arthroplasty device
CZ304512B6 (en) * 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Hyaluronic acid derivative, process for its preparation, modification process and use thereof
US8796234B2 (en) 2009-11-24 2014-08-05 Agency For Science, Technology And Research Crosslinking branched molecule through thiol-disulfide exchange to form hydrogel
US8883915B2 (en) 2008-07-07 2014-11-11 Biomimedica, Inc. Hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same
US9114024B2 (en) 2011-11-21 2015-08-25 Biomimedica, Inc. Systems, devices, and methods for anchoring orthopaedic implants to bone
US9403918B2 (en) 2009-12-11 2016-08-02 Contipro Pharma A.S. Oxidized derivative of hyaluronic acid, a method of preparation thereof and a method of modification thereof
US9434791B2 (en) 2009-12-11 2016-09-06 Contipro Pharma A.S. Method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US9999678B2 (en) 2012-11-27 2018-06-19 Contipro A.S. C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof
US10023658B2 (en) 2014-03-11 2018-07-17 Contipro A.S. Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof
US10414832B2 (en) 2015-06-26 2019-09-17 Contipro A.S Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof
US10457803B2 (en) 2008-07-07 2019-10-29 Hyalex Orthopaedics, Inc. Orthopedic implants having gradient polymer alloys
US10617711B2 (en) 2014-06-30 2020-04-14 Contipro A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof
US10618984B2 (en) 2016-06-27 2020-04-14 Contipro A.S. Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof
US10689464B2 (en) 2015-03-09 2020-06-23 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof
US10759878B2 (en) 2015-06-15 2020-09-01 Contipro A.S. Method of crosslinking of polysaccharides using photoremovable protecting groups
US10792392B2 (en) 2018-07-17 2020-10-06 Hyalex Orthopedics, Inc. Ionic polymer compositions
US11015016B2 (en) 2011-10-03 2021-05-25 Hyalex Orthopaedics, Inc. Polymeric adhesive for anchoring compliant materials to another surface
US11077228B2 (en) 2015-08-10 2021-08-03 Hyalex Orthopaedics, Inc. Interpenetrating polymer networks
US11129790B2 (en) 2017-05-19 2021-09-28 Northeastern University Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303738B1 (en) * 1998-11-11 2001-02-23 Aquisitio S P A CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS.
JP2001037472A (en) 1999-07-28 2001-02-13 Bio Quest:Kk Three dimensional cell-culturing base medium and cell culture using the same
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
AU2003205278B2 (en) * 2002-01-18 2008-08-07 Psivida Us Inc. Polymeric gel system for the controlled delivery of codrugs
ITPD20020064A1 (en) * 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl FOREIGN DERIVATIVES OF HYALURONIC ACID FOR THE PREPARATION OF HYDROGELD FOR USE IN THE BIOMEDICAL, SANITARY AND SURGICAL FIELD AND AS A SYSTEM
NZ536478A (en) * 2002-05-17 2008-02-29 Wyeth Corp Injectable or implantable solid, rod- shaped compositions for intraosseous delivery of osteogenic proteins
WO2004037164A2 (en) 2002-06-21 2004-05-06 University Of Utah Research Foundation Crosslinked compounds and methods of making and using thereof
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
WO2004060404A1 (en) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Drug carrier
US8138265B2 (en) 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US6982298B2 (en) 2003-01-10 2006-01-03 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8137688B2 (en) 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7465766B2 (en) 2004-01-08 2008-12-16 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
DE10318801A1 (en) * 2003-04-17 2004-11-04 Aesculap Ag & Co. Kg Flat implant and its use in surgery
US8073538B2 (en) 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
CA2549295C (en) * 2003-12-04 2016-05-03 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
JPWO2005054302A1 (en) * 2003-12-05 2007-12-06 中外製薬株式会社 Drug carrier and method for producing the same
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
JP4566189B2 (en) * 2004-03-15 2010-10-20 テルモ株式会社 Anti-adhesive material
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
CA2567532C (en) * 2004-05-20 2013-10-01 Mentor Corporation Methods for making injectable polymer hydrogels
US8137450B2 (en) * 2004-07-08 2012-03-20 Symatese Collagen-based lyophilised glue and the use thereof for producing an adhesive prosthesis
FR2873379B1 (en) * 2004-07-23 2008-05-16 Jerome Asius PROCESS FOR THE PREPARATION OF RETICULATED HYALURONIC ACID, RETICULATED HYALURONIC ACID WHICH CAN BE OBTAINED BY THIS METHOD, IMPLANT CONTAINING THE RETICULATED HYALURONIC ACID, AND USE THEREOF
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
CN102416020A (en) * 2004-12-30 2012-04-18 建新公司 Regiments for intra-articular viscosupplementation
US7825083B2 (en) * 2005-02-10 2010-11-02 Spine Wave, Inc. Synovial fluid barrier
JP2008531769A (en) 2005-02-23 2008-08-14 ズィマー・テクノロジー・インコーポレーテッド Blend hydrogel and method for producing the same
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US7858080B2 (en) 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
WO2007004675A1 (en) 2005-07-06 2007-01-11 Seikagaku Corporation Drug-containing photocrosslinked hyaluronic acid derivative gel
BRPI0615065A2 (en) * 2005-09-02 2011-05-03 Colbar Lifescience Ltd processes for preparing cross-linked polysaccharides, said polysaccharides, process for preparing a composite cross-linked matrix, and said matrix
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
US8053559B2 (en) 2005-10-27 2011-11-08 Coloplast A/S Biodegradable scaffold with ECM material
ATE494308T1 (en) * 2005-11-22 2011-01-15 Centre Nat Rech Scient NEW DERIVATIVES OF HYALURONIC ACID, PRODUCTION PROCESSES THEREOF AND USES THEREOF
AU2006321809A1 (en) 2005-12-07 2007-06-14 Zimmer, Inc. Methods of bonding or modifying hydrogels using irradiation
US8017107B2 (en) 2005-12-22 2011-09-13 Zimmer, Inc. Perfluorocyclobutane crosslinked hydrogels
WO2007102149A2 (en) 2006-03-07 2007-09-13 Prochon Biotech Ltd. Hydrazido derivatives of hyaluronic acid
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
RU2008144129A (en) * 2006-04-07 2010-05-20 Адосиа (Fr) BIFUNCTIONALIZED POLYSACCHARIDES
KR100803576B1 (en) * 2006-06-14 2008-02-15 주식회사 인피트론 A composition for transplant comprising adipose stem cells and adipocytes
EP1884231A1 (en) * 2006-08-01 2008-02-06 Auriga International S.A. Cosmetic or pharmaceutical composition containing hyaluronic acid
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
FR2908415B1 (en) * 2006-11-10 2009-01-23 Abr Dev Sarl RETICULATED HYALURONIC ACID AND PROCESS FOR PREPARING THE SAME
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
BRPI0722061B8 (en) * 2006-12-22 2021-06-22 Croma Pharma Ges M B H use of a polymer containing thiol group and implant
WO2008081463A2 (en) * 2007-01-04 2008-07-10 Hepacore Ltd. Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
EP2152743A2 (en) * 2007-05-23 2010-02-17 Allergan, Inc. Cross-linked collagen and uses thereof
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US7731988B2 (en) 2007-08-03 2010-06-08 Zimmer, Inc. Multi-polymer hydrogels
US8062739B2 (en) 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US7947784B2 (en) 2007-11-16 2011-05-24 Zimmer, Inc. Reactive compounding of hydrogels
MX2010005331A (en) 2007-11-16 2010-08-11 Vicept Therapeutics Inc Compositions and methods for treating purpura.
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8034362B2 (en) 2008-01-04 2011-10-11 Zimmer, Inc. Chemical composition of hydrogels for use as articulating surfaces
US8080260B2 (en) 2008-02-13 2011-12-20 The Cleveland Clinic Foundation Molecular enhancement of extracellular matrix and methods of use
US8668863B2 (en) 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
EP2300042A4 (en) 2008-04-30 2012-05-02 Cleveland Clinic Foundation Compositions and methods to treat urinary incontinence
EP2280739B1 (en) * 2008-06-03 2012-07-04 Actamax Surgical Materials LLC A tissue coating for preventing undesired tissue-to-tissue adhesions
US20100015231A1 (en) * 2008-07-17 2010-01-21 E.I. Du Pont De Nemours And Company Low swell, long-lived hydrogel sealant
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
DE102008048227A1 (en) 2008-09-18 2010-04-01 Friedrich-Schiller-Universität Jena Producing polyelectrolyte hydrogel bodies, useful e.g. as soft tissue implants, comprises filling a semi-permeable membrane-forming liquid and a coagulation medium in a hollow template to form hollow semipermeable membrane body
JP5788323B2 (en) 2008-10-02 2015-09-30 エル.アール. アールアンドディー リミテッド Interfacial layer wound dressing
CN101721349B (en) 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 Injectable in-situ crosslinking aquogel and preparation method and application thereof
US9044529B2 (en) * 2008-11-19 2015-06-02 Actamax Surgical Materials, Llc Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
US20100160960A1 (en) * 2008-12-19 2010-06-24 E. I. Du Pont De Nemours And Company Hydrogel tissue adhesive having increased degradation time
US8273373B2 (en) * 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
ES2621380T3 (en) * 2009-04-02 2017-07-03 Allergan, Inc. Hair-shaped hydrogels for soft tissue augmentation
JP2012523289A (en) 2009-04-09 2012-10-04 アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー Hydrogel tissue adhesive with reduced degradation time
WO2010138074A1 (en) * 2009-05-29 2010-12-02 Hilborn Joens Hyaluronic acid based delivery systems
SG176286A1 (en) 2009-05-29 2012-01-30 Agency Science Tech & Res Flavonoid hydrogel
IT1399351B1 (en) * 2009-06-16 2013-04-16 Fidia Farmaceutici PROCEDURE FOR THE SYNTHESIS OF GLYCOSAMINOGLICAN CONJUGATES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMERIC CONJUGATES AND RELATIVE USES
US8796242B2 (en) 2009-07-02 2014-08-05 Actamax Surgical Materials, Llc Hydrogel tissue adhesive for medical use
US8580951B2 (en) * 2009-07-02 2013-11-12 Actamax Surgical Materials, Llc Aldehyde-functionalized polysaccharides
EP2448604B1 (en) 2009-07-02 2016-03-23 Actamax Surgical Materials LLC Hydrogel tissue adhesive for medical use
JP2013506681A (en) 2009-10-02 2013-02-28 バクスター・インターナショナル・インコーポレイテッド Hematopoietic stem cells for use in the treatment of kidney injury
CN102781463A (en) 2009-10-07 2012-11-14 戈诺珍公司 Methods and compositions for skin regeneration
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
TWI510501B (en) * 2009-12-08 2015-12-01 Kewpie Corp Method for manufacturing purified hyaluronic acid group
FR2954945B1 (en) 2010-01-04 2012-01-06 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION, COSMETIC PROCESSING METHOD, AND HYALURONIC ACID DERIVATIVE
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
EP2544652A2 (en) 2010-03-12 2013-01-16 Allergan Industrie SAS A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition.
ES2729994T3 (en) * 2010-03-22 2019-11-07 Allergan Inc Crosslinked polysaccharide and protein polysaccharide hydrogels for soft tissue augmentation
US9012415B2 (en) 2010-03-26 2015-04-21 Stemmatters, Biotecnologia E Medicina Regenerativa S.A. Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof
WO2011126839A2 (en) * 2010-03-29 2011-10-13 Surmodics Pharmaceuticals, Inc. Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
CN102399295B (en) 2010-09-09 2013-11-06 常州百瑞吉生物医药有限公司 Low-sulfhydrylation-modification-degree biocompatible high-molecular sulfhydrylation derivatives, cross-linking material thereof, and purpose thereof
JP6042815B2 (en) 2010-10-08 2016-12-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
WO2012054784A1 (en) 2010-10-20 2012-04-26 Li-Cor, Inc. Fluorescent imaging with substituted cyanine dyes
EP2670439B1 (en) * 2011-01-31 2019-03-13 PVAC Medical Technologies Ltd. Active principle for mitigating undesired medical conditions
WO2012118189A1 (en) 2011-03-03 2012-09-07 中外製薬株式会社 Hyaluronic acid derivative modified by amino-carbonic acid
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
JP5998201B2 (en) 2011-04-20 2016-09-28 カービラン セラピューティクス, インコーポレイテッド IN-SITU gel-forming composition
US20140256831A1 (en) * 2011-05-31 2014-09-11 The University Of Tokyo Hydrogel and method for producing same
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US20220023186A1 (en) * 2011-06-03 2022-01-27 Allergan, Inc. Dermal filler compositions
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
AU2015255254B2 (en) * 2011-09-14 2017-07-06 Allergan Industrie, Sas Dermal filler compositions for fine line treatment
TWI561535B (en) 2011-10-06 2016-12-11 Bvw Holding Ag Copolymers of hydrophobic and hydrophilic segments that reduce protein adsorption
ES2798109T3 (en) * 2012-01-25 2020-12-09 Univ Akron Polymerizable fluorinated hydrogels for wound dressings and procedures for making them
WO2013126590A2 (en) 2012-02-21 2013-08-29 Baxter International Inc. Pharmaceutical composition comprising cd34+ cells
CZ304266B6 (en) 2012-11-27 2014-02-05 Contipro Biotech S.R.O. Endless fibers based on hyaluronate selectively oxidized in position 6 N-acetyl-D-glucosamine portion, their preparation, use, threads, yarns, fabrics and process for preparing thereof
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
US20140315828A1 (en) 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions
US20160184474A1 (en) 2013-07-29 2016-06-30 Actamax Surgical Materials, Llc Low swell tissue adhesive and sealant formulations
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
WO2015142721A1 (en) * 2014-03-16 2015-09-24 Drexel University Novel hydrogels and methods using same
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
EP3040348A1 (en) * 2014-12-29 2016-07-06 Galderma S.A. Graft copolymer
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
US10563164B1 (en) 2015-10-08 2020-02-18 Charm Sciences, Inc. Plate reader
EP3156044A1 (en) 2015-10-16 2017-04-19 Merz Pharma GmbH & Co. KGaA In situ cross-linkable polysaccharide compositions and uses thereof
RU2748235C2 (en) 2015-12-29 2021-05-21 Гальдерма С.А. Method for deacetylation of biopolymers
US10495563B1 (en) 2016-04-28 2019-12-03 Charm Sciences, Inc. Plate reader observation methods and operation
EP3241895A1 (en) * 2016-05-04 2017-11-08 ETH Zürich, ETH Transfer Transglutaminase mediated high molecular weight hyaluronan hydrogels
PT3623390T (en) * 2016-05-31 2023-10-27 Galderma Sa Carbohydrate crosslinker
WO2017218532A1 (en) * 2016-06-13 2017-12-21 Purdue Research Foundation Responsive elastic polymers and methods of making and using same
AU2017315431B2 (en) 2016-08-24 2020-06-25 Allergan, Inc. Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation
WO2018067545A1 (en) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Chondroprotective nanoparticles for the treatment of osteoarthritis
KR101877894B1 (en) * 2016-12-09 2018-07-12 서울대학교병원 Injectable combination drug for treating hearing loss and method of preparing the same
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US20230190997A1 (en) 2017-06-26 2023-06-22 Evolved By Nature, Inc. Silk-hyaluronic acid based tissue filers and methods of using the same
WO2019121488A1 (en) * 2017-12-21 2019-06-27 Nicox S.A. Nitric oxide releasing hyaluronic esters
CN108721695A (en) * 2018-05-29 2018-11-02 金陵科技学院 A kind of preparation method of syringeability composite hydrogel cell carrier holder
BR112020024735B1 (en) 2018-06-15 2024-02-27 Croma Pharma Gmbh STERILE HYDROGEL COMPOSITION, ITS USE AND PRODUCTION METHODS, SOFT TISSUE FILLING, AND IMPLANTATION OR DEPOSIT
KR20210021361A (en) 2018-06-15 2021-02-25 크로마-파르마 게엠베하 Hydrogel composition containing crosslinked polymer
JP2022512363A (en) 2018-12-19 2022-02-03 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー Aldehyde-modified hyaluronic acid, methods for preparing it and its uses
US11667895B2 (en) 2019-05-10 2023-06-06 The Board Of Trustees Of The University Of Alabama Methods and devices related to controlled delivery of phages as a theranostic tool
CN110279610B (en) 2019-06-26 2021-06-11 常州百瑞吉生物医药有限公司 Hyaluronic acid skin protection composition and preparation method and application thereof
US20230133656A1 (en) * 2019-07-03 2023-05-04 Molly Sandra Shoichet Hydrogel compositions and uses thereof
MX2022006677A (en) 2019-12-02 2022-07-27 Galderma Holding SA High molecular weight esthetic compositions.
EP4077402A1 (en) 2019-12-19 2022-10-26 Croma-Pharma Gesellschaft m.b.H. Thiol-modified hyaluronan and hydrogel comprising the crosslinked hyaluronan
CN113929792B (en) * 2020-07-13 2023-03-10 孛朗孚(杭州)生物科技有限公司 Aldehyde modified hyaluronic acid (sodium) and synthesis method and application thereof
CN113583262B (en) * 2021-06-24 2022-03-29 四川大学 Near-infrared response hyaluronic acid hydrogel for articular cartilage repair and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462976A (en) * 1992-02-05 1995-10-31 Seikagaku Kogyo Kabushiki Kaisha Photocurable glycosaminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US5512329A (en) * 1982-09-29 1996-04-30 Bsi Corporation Substrate surface preparation
US4517295A (en) 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
US5316926A (en) 1983-11-25 1994-05-31 Miles Inc. Method for the microbiological production of non-antigenic hyaluronic acid
CA1295796C (en) 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
JPS60251898A (en) 1984-05-25 1985-12-12 Shiseido Co Ltd Preparation of hyaluronic acid by fermentation method
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4780414A (en) 1985-01-18 1988-10-25 Bio-Technology General Corp. Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
DE3608158A1 (en) 1986-03-12 1987-09-17 Braun Melsungen Ag VESSELED PROSTHESIS IMPREGNATED WITH CROSSLINED GELATINE AND METHOD FOR THE PRODUCTION THEREOF
IT1198449B (en) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1990006767A1 (en) 1988-12-20 1990-06-28 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
US4897349A (en) 1989-04-28 1990-01-30 Medchem Products, Inc. Biosynthesis of hyaluronic acid
US5356883A (en) 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
WO1992006714A1 (en) * 1990-10-18 1992-04-30 Shiseido Co., Ltd. Combination of hyaluronic acid with medicinal ingredient and production thereof
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5219360A (en) * 1991-05-10 1993-06-15 Fortis Research Corporation Mammary prosthesis fill and method of making same
WO1993000050A1 (en) * 1991-06-21 1993-01-07 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
FR2679778B1 (en) 1991-08-02 1995-07-07 Coletica USE OF CROLAGEN CROSSLINKED BY A CROSSLINKING AGENT FOR THE MANUFACTURE OF A SLOW RESORPTIVE, BIOCOMPATIBLE, SUTURABLE MEMBRANE, AS WELL AS SUCH A MEMBRANE.
US5270300A (en) 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
GB2261672A (en) 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
GB9206509D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges containing active agents
IL105529A0 (en) 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
US5565210A (en) 1993-03-22 1996-10-15 Johnson & Johnson Medical, Inc. Bioabsorbable wound implant materials
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
IT1268955B1 (en) * 1994-03-11 1997-03-18 Fidia Advanced Biopolymers Srl ACTIVE ESTERS OF CARBOXYL POLYSACCHARIDES
US5769899A (en) 1994-08-12 1998-06-23 Matrix Biotechnologies, Inc. Cartilage repair unit
US6025444A (en) * 1994-11-17 2000-02-15 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Cinnamic acid derivative
IT1269274B (en) 1994-11-22 1997-03-26 Carlo Antonio Camorani METHOD FOR FORMING CERAMIC TILES AND RELATED PLANT
US5693341A (en) 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents
US5817303A (en) * 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
AU722250B2 (en) 1995-11-15 2000-07-27 Seikagaku Corporation Photocured crosslinked-hyaluronic acid gel and method of preparation thereof
CA2256400A1 (en) 1996-05-28 1997-12-04 Brown University Research Foundation Hyaluronan based biodegradable scaffolds for tissue repair
FR2754267B1 (en) 1996-10-07 1999-01-22 Dev Des Utilisations Du Collag PROCESS FOR CROSSLINKING COLLAGEN OR GELATIN USING A MACROMOLECULAR POLYALDEHYDE AND ADHESIVE COMPOSITION
AU3870099A (en) * 1998-04-28 1999-11-16 Jagotec Ag Hyaluronan-based imaging agents
KR20010025040A (en) * 1998-05-20 2001-03-26 나가야마 오사무 Remedies for joint diseases bound to hyaluronic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462976A (en) * 1992-02-05 1995-10-31 Seikagaku Kogyo Kabushiki Kaisha Photocurable glycosaminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679190B2 (en) 2004-10-05 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Hydrogel arthroplasty device
US9387082B2 (en) 2004-10-05 2016-07-12 The Board Of Trustees Of The Leland Stanford Junior University Hydrogel arthroplasty device
US7674781B2 (en) * 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
US20070293648A1 (en) * 2006-04-28 2007-12-20 Heather Sheardown Hyaluronic acid-retaining polymers
US20100279952A1 (en) * 2007-12-21 2010-11-04 Ninus Caram-Lelham Cross-linked hydrogel containing an active substance
EP3456749A1 (en) 2008-02-29 2019-03-20 PVAC Medical Technologies Ltd. A substituted polyvinyal alcohol reagent
US9585987B2 (en) 2008-02-29 2017-03-07 Pvac Medical Technologies Ltd Composition for the formation of gels
US20110008444A1 (en) * 2008-02-29 2011-01-13 Ipr-Systems Sweden Ab Composition for the formation of gels
US10752768B2 (en) 2008-07-07 2020-08-25 Hyalex Orthopaedics, Inc. Orthopedic implants having gradient polymer alloys
US10457803B2 (en) 2008-07-07 2019-10-29 Hyalex Orthopaedics, Inc. Orthopedic implants having gradient polymer alloys
US8883915B2 (en) 2008-07-07 2014-11-11 Biomimedica, Inc. Hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same
US8853294B2 (en) 2008-08-05 2014-10-07 Biomimedica, Inc. Polyurethane-grafted hydrogels
US8497023B2 (en) 2008-08-05 2013-07-30 Biomimedica, Inc. Polyurethane-grafted hydrogels
US8742013B2 (en) * 2009-04-24 2014-06-03 Seoul National University of Technology Center for Industrial Collaboration Synthesis of lipoamide-grafted high molecular compound and method therefor
US20100272761A1 (en) * 2009-04-24 2010-10-28 Seoul National University of Technology Center for Industrial Collaboration Synthesis of lipoamide-grafted high molecular compound and method therefor
US9132201B2 (en) * 2009-11-11 2015-09-15 University Of Twente, Institute For Biomedical And Technical Medicine (Mira) Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
US20120301441A1 (en) * 2009-11-11 2012-11-29 Hermanus Bernardus Johannes Karperien Dextran-hyaluronic acid based hydrogels
US20120276069A1 (en) * 2009-11-11 2012-11-01 Hermanus Bernardus Johannes Karperien Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers
US8796234B2 (en) 2009-11-24 2014-08-05 Agency For Science, Technology And Research Crosslinking branched molecule through thiol-disulfide exchange to form hydrogel
US9434791B2 (en) 2009-12-11 2016-09-06 Contipro Pharma A.S. Method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof
US9403918B2 (en) 2009-12-11 2016-08-02 Contipro Pharma A.S. Oxidized derivative of hyaluronic acid, a method of preparation thereof and a method of modification thereof
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8927491B2 (en) 2010-12-28 2015-01-06 Depuy Mitek, Llc Methods for forming compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US11090328B2 (en) 2010-12-28 2021-08-17 Medos International Sarl Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US9561260B2 (en) 2010-12-28 2017-02-07 Depuy Mitek, Llc Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
WO2013036072A1 (en) * 2011-09-08 2013-03-14 신풍제약 주식회사 Injectable therapeutic agent for arthritis
US11760830B2 (en) 2011-10-03 2023-09-19 Hyalex Orthopaedics, Inc. Polymeric adhesive for anchoring compliant materials to another surface
US11015016B2 (en) 2011-10-03 2021-05-25 Hyalex Orthopaedics, Inc. Polymeric adhesive for anchoring compliant materials to another surface
US9114024B2 (en) 2011-11-21 2015-08-25 Biomimedica, Inc. Systems, devices, and methods for anchoring orthopaedic implants to bone
CZ303879B6 (en) * 2012-02-28 2013-06-05 Contipro Biotech S.R.O. Derivatives based on hyaluronic acid capable of forming hydrogels, process of their preparation, hydrogels based on these derivatives, process of their preparation and use
US9492586B2 (en) 2012-02-28 2016-11-15 Contipro Biotech S.R.O. Derivatives of hyaluronic acid capable of forming hydrogels
US9522966B2 (en) 2012-08-08 2016-12-20 Contipro Biotech S.R.O. Hyaluronic acid derivative, method of preparation thereof, method of modification thereof and use thereof
CZ304512B6 (en) * 2012-08-08 2014-06-11 Contipro Biotech S.R.O. Hyaluronic acid derivative, process for its preparation, modification process and use thereof
US9999678B2 (en) 2012-11-27 2018-06-19 Contipro A.S. C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof
US10023658B2 (en) 2014-03-11 2018-07-17 Contipro A.S. Conjugates of oligomer of hyaluronic acid or of a salt thereof, method of preparation thereof and use thereof
US10617711B2 (en) 2014-06-30 2020-04-14 Contipro A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof
US10532069B2 (en) 2015-01-20 2020-01-14 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
US10689464B2 (en) 2015-03-09 2020-06-23 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof
US10759878B2 (en) 2015-06-15 2020-09-01 Contipro A.S. Method of crosslinking of polysaccharides using photoremovable protecting groups
US10414832B2 (en) 2015-06-26 2019-09-17 Contipro A.S Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof
US11077228B2 (en) 2015-08-10 2021-08-03 Hyalex Orthopaedics, Inc. Interpenetrating polymer networks
US10618984B2 (en) 2016-06-27 2020-04-14 Contipro A.S. Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof
US11129790B2 (en) 2017-05-19 2021-09-28 Northeastern University Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates
US10792392B2 (en) 2018-07-17 2020-10-06 Hyalex Orthopedics, Inc. Ionic polymer compositions
US10869950B2 (en) 2018-07-17 2020-12-22 Hyalex Orthopaedics, Inc. Ionic polymer compositions
US11110200B2 (en) 2018-07-17 2021-09-07 Hyalex Orthopaedics, Inc. Ionic polymer compositions
US11364322B2 (en) 2018-07-17 2022-06-21 Hyalex Orthopaedics, Inc. Ionic polymer compositions

Also Published As

Publication number Publication date
IL142068A0 (en) 2002-03-10
AU6192299A (en) 2000-04-10
DE69922522D1 (en) 2005-01-13
CA2344215A1 (en) 2000-03-30
WO2000016818A1 (en) 2000-03-30
EP1115433B1 (en) 2004-12-08
WO2000016818A9 (en) 2000-08-24
EP1757314A1 (en) 2007-02-28
IL142068A (en) 2006-10-05
EP1115433A1 (en) 2001-07-18
DE69922522T2 (en) 2005-12-15
US7196180B2 (en) 2007-03-27
ATE284229T1 (en) 2004-12-15
US6630457B1 (en) 2003-10-07
US20040072793A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
US6630457B1 (en) Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
Bulpitt et al. New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels
Ziadlou et al. Optimization of hyaluronic acid-tyramine/silk-fibroin composite hydrogels for cartilage tissue engineering and delivery of anti-inflammatory and anabolic drugs
US8329870B2 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
Park et al. Photopolymerized hyaluronic acid-based hydrogels and interpenetrating networks
US8691793B2 (en) Modified macromolecules and associated methods of synthesis and use
US6303585B1 (en) Cross-linked polysaccharide drug carrier
AU771409B2 (en) Injectable hyaluronic acid derivative with pharmaceuticals/cells
CA2239775C (en) Crosslinked polymer compositions and methods for their use
US8940888B2 (en) Hydrazido derivatives of hyaluronic acid
US20120301441A1 (en) Dextran-hyaluronic acid based hydrogels
US20080032920A1 (en) Macromolecules modified with electrophilic groups and methods of making and using thereof
US20090124540A1 (en) Anti-adhesion composites and methods of use thereof
KR100737954B1 (en) Injectable hydrogels based on hyaluonic acid for tissue regeneration
CA2428748A1 (en) Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
JPH07196704A (en) Ionically cross-linked glycosaminoglycan gel for soft- tissue strengthening and drug transport
AU2002223995A1 (en) Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants
US11707473B2 (en) Method for the manufacture and use of a bionic hydrogel composition for medical applications
Jeong et al. Supramolecular injectable hyaluronate hydrogels for cartilage tissue regeneration
US20130084278A1 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
US20090047740A1 (en) Culture aid for cells and tissues
Shalaby et al. Hyaluronic Acid-Based Systems

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION